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In recent years, various enzymes involved in cancer cell metabolism are getting a lot of interest 
as potential targets for the small molecule development towards cancer therapy. Glutaminase is 
the key enzyme responsible for catalysing the conversion of glutamine to glutamate, and 
represents the first step in glutamine metabolism (glutaminolysis). This process provides the 
cancer cell with high energy requirements to meet their accelerated growth and proliferation. In 
humans, two major glutaminase isoforms - KGA (Kidney-type glutaminase) and LGA (Liver-
type glutaminase) have been reported. The KGA isoform is over expressed in several tumour 
types such as lymphoma, prostate, brain and kidney cancers, and it has become an attractive 
cancer target for small molecules. However, the structural and molecular basis of KGA 
inhibition and how the function of KGA is regulated in the cancer cells are still not clearly 
understood. In this thesis we report our structural and functional studies on KGA and its 
implications in cancer cell metabolism.  
 
Chapter I provides a general introduction based on the detailed literature survey on cancer cell 
metabolism and a key metabolic enzyme, glutaminase. In the chapter II we report the allosteric 
inhibition mechanism of KGA by a small molecule inhibitor BPTES [bis-2-(5-phenylacetamido-
1,2,4-thiadiazol-2-yl) ethyl sulfide] and further we identified Raf-Mek-Erk signaling pathway as 
the regulator of KGA. On the basis of crystal structures, we reveal that BPTES binds to an 
allosteric pocket at the dimer interface of KGA, triggering a dramatic conformational change of the 
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key loop (Glu312-Pro329) near the catalytic site and rendering it inactive. The binding mode of 
BPTES on the hydrophobic pocket explains its specificity to KGA. Interestingly, KGA activity in 
cells is stimulated by EGF, and KGA associates with all three kinase components of the Raf-
1/Mek2/Erk signaling module. However, the enhanced activity is abrogated by kinase-dead, 
dominant negative mutants of Raf-1 (Raf-1-K375M) andMek2 (Mek2-K101A), protein 
phosphatase PP2A, and Mek-inhibitor U0126, indicative of phosphorylation-dependent regulation. 
Furthermore, treating cells that coexpressed Mek2- K101A and KGA with suboptimal level of 
BPTES leads to synergistic inhibition on cell proliferation. Consequently, mutating the crucial 
hydrophobic residues at this key loop abrogates KGA activity and cell proliferation, despite the 
binding of constitutive active Mek2-S222/226D. These studies therefore offer insights into (i) 
allosteric inhibition of KGA by BPTES, revealing the dynamic nature of KGA’s active and 
inhibitory sites, and (ii) cross-talk and regulation of KGA activities by EGF-mediated Raf-Mek-
Erk signaling. Chapter III of this thesis reports the crystal structure of catalytic domain of KGA in 
complex with DON (6-Diazo-5-oxo-L-norlucine), an active site inhibitor. The complex structure 
revealed the DON binding pocket of KGA that form a covalent bond with active site residue 
Ser286 of KGA. Further we performed site-directed mutagenesis to validate the importance of key 
residues from the active site to understand the active site inhibition mechanism of KGA. The 
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Among the top killer diseases, cancer is a leading cause of death and it continues to be a 
major public health problem around the world. According to World Health Organization 
(WHO) statistics, cancer caused 7.6 million deaths (13% of all deaths) in 2008, and by 
2030, it is expected to increase to 13.1 million deaths worldwide (estimated by WHO) 
(Boyle P, 2008). Cancer is the term for complex diseases characterized by many 
physiological changes that lead to uncontrolled cell growth. Cells are basic unit of life; 
they grow and divide to produce more healthy cells in a controlled manner (e.g. by 
growth factor control). However, sometimes, cells do not function normally; they keep 
dividing and produce more cells in an uncontrolled manner (abnormal growth), which 
also invades surrounding tissues. This unregulated growth of cells ultimately leads to 
form a clump of tissue called a tumor. The processes by which normal cells are 
transformed into cancer cells are still not well understood and has remained as a key 
biological question yet to be answered (Anand et al., 2008; Seyfried and Shelton, 2010).  
 
1.1.1 The Hallmark of Cancers  
In a recent review, Hanahan and Weinberg proposed six common hallmark features that 
can underlie the transformation of normal cells to cancer cells (Hanahan and Weinberg, 
2000, 2011). These six hallmark features are believed to be shared by most cancers 
(Figure 1). It includes followings: 
 
(1) Cancer cells stimulate their self-growth signals (uncontrolled proliferation) 
(2) Resistance towards antigrowth signals 
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(3) Resistance towards apoptosis (programmed cell death) 
(4) Promoting angiogenesis 
(5) Limitless multiplication potential 
(6) Tissue invasion and spread to distant sites (metastasis)  
Apart from these six common features of cancer, Warburg effect or aerobic glycolysis is 
also now recognized as a hallmark of most cancer cells (Gatenby and Gillies, 2004; 
Seyfried et al., 2008).  
 
 
Figure 1: The hallmark features of cancer cells. This figure is adapted from (Hanahan 






1.2 Cancer Cell Metabolism  
In the 1920s, Otto Warburg first observed that the cancer cells metabolize glucose in a 
way different from normal cells (Warburg et al., 1927). He demonstrated that cancer cells 
exhibit increased uptake of glucose in which glucose is converted to lactate, even in the 
presence of oxygen, termed as the “Warburg Effect” (Brahimi-Horn et al., 2007; 
WARBURG, 1956a; Warburg, 1956b; Warburg et al., 1960a; WARBURG et al., 
1960b)Otto Warburg received Nobel Prize of Physiology or Medicine in 1931 for his 
discovery of “altered metabolism in cancer”. The Warburg Effect is a unique metabolism 
that is observed in most cancer cells and not found in normal cells (Vander Heiden et al., 
2009). The phenomenon of Warburg effect is now broadly accepted, which formed a 
basis for the recent research on the cancer cell metabolism. The metabolic alteration is 
essential to facilitate the incorporation of nutrients into bioenergetics and biosynthetic 
requirements of cell survival and metabolism (Bauer et al., 2005; Locasale and Cantley, 
2010; Vander Heiden, 2011). Figure 2 emphasizes the timeline in the development of 









1.2.1 Glucose Metabolism in Normal cells  
In normal cells, glucose is completely metabolized by the following linked metabolic 
pathways:  
a) Glycolysis  
b) Tricarboxylic acid (TCA) cycle 
c) Oxidative phosphorylation  
Glucose is initially metabolized through glycolysis that takes place in the cytoplasm of a 
cell. This process involves a series of enzymatic reactions which ultimately produces two 
molecules of pyruvate and two ATPs from one glucose molecule (Figure 3). The 
generated pyruvate enters mitochondria and is converted to acetyl CoA by the action of 
pyruvate dehydrogenase (PDH). Condensation of acetyl CoA with oxaloacetate (OAA) is 
catalyzed by the enzyme citrate synthetase to form citrate in the TCA (tricarboxylic acid) 
cycle.  Citrate is further completely oxidized in mitochondria to produce a variety of six- 
and three-carbon intermediates, and results in production of thirty-six ATPs molecules at 
the end of oxidative phosphorylation (Lehninger, 1945). Thus, in total thirty-eight ATPs 
are produced from a single molecule of glucose, when oxygen is present. By this process, 
glucose satisfies the cells with most energy (90%) requirements (Vander Heiden et al., 
2009). On the other hand, the series of reactions involved in the conversion of glucose to 
lactate in the absence of oxygen, is called anaerobic respiration or fermentative 






1.2.2 Altered Glucose metabolism in Cancer cells (Warburg effect)  
In order to satisfy the cellular energy demands in the normal cells, the end product of 
glycolysis, pyruvate enters into mitochondria to generate ATP through the TCA cycle. 
However, in cancer cells, the pyruvate has shown to be directed away from the TCA 
cycle and is converted to lactate by the enzyme lactate dehydrogenase (LDH). In a typical 
cell, this lactate production only happens in anaerobic conditions, but, cancer cells are 
able to produce lactate even when oxygen is available, a process termed “aerobic 
glycolysis” or the Warburg Effect (WARBURG, 1956a) (Figure 3). The importance of 
Warburg effect is experimentally validated in most of the cancer cells, where increased 
glucose uptake is found, which thereby promotes the formation of tumors (Altenberg and 
Greulich, 2004; Kroemer and Pouyssegur, 2008; Ortega et al., 2009; Schnelzer et al., 
2000).  
 
According to Otto Warburg, most cancer cells are highly reliant on aerobic glycolysis and 
not on the mitochondrial function (citric acid cycle and oxidative phosphorylation) for 
their energy needs. Since the cancer cells depend on less efficient glycolysis which serves 
only 2 ATP molecules (Figure 3), they require additional glucose to satisfy their 
increased cellular energy demands. Hence, in contrast to normal cells (which produces 38 
ATP molecules), cancer cells need to use 19 more glucose molecules to generate (2 ATP 
X 19 glucose=38 ATP) equivalent 38ATP molecules. The enhanced glucose uptake of 
cancer cells or the Warburg effect is experimentally proved through the recent imaging 
studies called positron emission topography (PET) imaging. The PET imaging is very 





Figure 3: Modes of glucose metabolism in normal and cancer cells. In the presence of 
oxygen, a normal cell (differentiated) metabolizes glucose via glycolysis, TCA and 
oxidative phosphorylation to generate ATP. Cancer cells (proliferative) tend to convert 
most glucose to lactate, even in the presence of oxygen (aerobic glycolysis). This figure 
is adapted from (Vander Heiden et al., 2009).  
 
To assess the glucose intake of tumors, a radio-active glucose analogue, 18F-FDG (2-
dexoy-2-(18F) fluoro-D-glucose, is injected into patients and a PET scanner is used to 
image the distribution of FDG around the body (Ben-Haim and Ell, 2009; Mankoff et al., 
2007). The imaging technique is currently being used not only in diagnosis of human 
tumors but also in staging and monitoring growth of tumors (López-Ríos et al., 2007). 
The Warburg effect in cancer cells is backed by various explanations. One possible 
explanation is that the abnormal activity of metabolism-related enzymes from different 
9 
 
signaling pathways is responsible for promoting the Warburg effect (Teicher et al., 2012). 
For example, the activity of the enzyme pyruvate kinase that converts 
phosphoenolpyruvate into pyruvate in the glycolytic pathway was found to be different in 
many cancer cells (Christofk et al., 2008a). Two different isoforms of Pyruvate kinase 
(PK) have been known; PKM1 and PKM2. The PKM2 isoform is specifically up-
regulated in most cancer cells, but not in the normal cells (Mazurek et al., 2005). 
Interestingly, pyruvate kinase (PKM2) was suggested to bypass the pyruvate into lactate 
production pathway or alternative glycolytic pathway (Figure 4) (Christofk et al., 2008b; 
Hitosugi et al., 2009). To accommodate this alternative glycolytic pathway, the cancer 
cells appear to adopt increased rates of glutamine metabolism not only to produce ATP 
but also for the synthesis of macromolecular precursors such as nucleotides, certain 
amino acids, and fatty acids, and to generate energetic biomass (DeBerardinis et al., 
2008; DeBerardinis et al., 2007). 
 
1.2.3 Glutamine Metabolism in Cancer Cells (Glutaminolysis)  
Glutamine is the second major energy source for many cancer cells (Lu et al., 2010). 
Cancer cells are highly dependent on alternative glycolysis (pyruvate to lactate), and 
therefore only less pyruvate is processed to generate ATP through mitochondrial TCA 
cycle (truncated TCA cycle in cancer cells), and results in impaired mitochondrial 
function. Since TCA cycle is crucial for generating energy intermediates, the cancer cells 
must find an alternative mechanism to replenish this cycle. Accordingly, many cancer 
cells utilize the glutamine metabolism (known as glutaminolysis) as a new energy source. 
Once glutamine is taken by the cell, mitochondrial glutaminase converts glutamine into 
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glutamate (Figure 4 and Figure 5). Glutamate is then converted into α-ketoglutarate 
through deamination process catalyzed by the enzyme glutamate dehydrogenase.  
 
 
Figure 4: Metabolic differences observed between normal cells and cancer cells. In 
normal cells, glucose is concerted to acetyl CoA (yellow) and is further metabolized via 
TCA cycle (green). In cancer cells, pyruvate is primarily used to generate lactate. The 
pyruvate kinase M2 isoform (PKM2, tumor specific isoform) prevents the pyruvate entry 
to mitochondria. To accommodate this, cancer cells utilize a process called 
glutaminolysis, as an alternate source to replenishing the TCA cycle and energy 
synthesis. Glutaminase is the key enzyme, which converts glutamine to glutamate and 
opens up the glutaminolysis process. This figure is adapted from (Erickson and Cerione, 
2010). 
 
This α-ketoglutarate in turn enters the TCA cycle and is eventually metabolized to 
produce oxaloacetate, which condenses with acetyl-coA (generated from glucolysis) to 
generate citrate. In effect, the glutamine metabolism acts as new energy producing 
pathway, that generates various metabolic intermediates glutamate, aspartate, malate, 
pyruvate, citrate, alanine, and lactate (Dang, 2010a) (Figure 5). In the glutaminolytic 
pathway, degradation of both amino acids glutamine and glutamate plays a key role in 
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anabolic process (Dang, 2010a). The donor amino group of glutamine acts as a precursor 
for the synthesis of certain amino acids like proline, ornithine, and arginine (Wise and 
Thompson, 2010). Glutaminolysis is also essential for the generation of a series of 
intermediates from different metabolic cascades: for example (a) synthesis of acetyl CoA 
serine (for protein and nucleotide synthesis) and for NADH generation (for lipid, 
nucleotide synthesis and redox balance) (Wise et al., 2008). In addition, the citrate 
generated through glutaminolysis is found to be essential for fatty acids and cholesterol 
synthesis (Figure 5) (Dang, 2010b; Wise and Thompson, 2010). Notably, key co-factors 
such as glutathione, NADH and NADPH generated from glutamine are shown to play 
key role in protecting the cancer cells from oxidative stress (Dang, 2010b; DeBerardinis 
et al., 2008). Several recent studies have shown that glutaminolysis is a key metabolic 
process occurring in many tumor cells. Indeed, cell culture studies indicate that many 
cancer cells cannot survive without glutamine, often referred to as “glutamine addiction” 
(Wise et al., 2008; Wise and Thompson, 2010). The enhanced glutamine metabolism in 
the cancer cells is particularly apparent with the observation of ammonium ion release 
from the venous effluent of the cancer-bearing patients (Fischer and Chance, 1990; 
Souba, 1993). 
 
Recent imaging techniques coupled with the improved methods such as nuclear magnetic 
resonance spectroscopy (NMR) and mass spectrometry (MS) play a key role in 
quantifying the glutamine metabolism in cancer cells (Wise et al., 2008). These 
techniques will help in identifying the specific metabolites that can be compared in 
cancer cells versus normal cells. The significance of glutaminolysis is supported by 13C -
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NMR measurements, suggesting cancer cells consume approximately 60% of glutamine 
for the conversion of lactate or alanine (DeBerardinis et al., 2008). 
  
Figure 5: Schematic diagram showing the connection between the glycolysis and 
glutaminolysis. Cancer cells use both pathways to meet their energy demands. In addition 
to glucose metabolism, cancer cells undergo glutaminolysis to generate high energy-
intermediates. This figure is adapted from (http://www.herbalzym.com/wp-
content/uploads/2010/09/glutaminolysis.jpg).   
 
Currently it is believed that targeting the metabolic enzymes which are particularly 
critical for feeding glutamine to the cancer cells, will have therapeutic impact against 
many cancers. Glutaminase expression has been shown to be increased in several tumour 
types such as lymphoma, prostate, brain (glioblastoma) and kidney cancers (Gao et al., 
2009; Seltzer et al., 2010). Thus, glutaminase has become an attractive target for the 
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development of small molecules against cancer therapy. In the next section, I will briefly 
discuss the role of signaling pathways that regulates the cancer metabolism.  
 
1.3 Signal Transduction  
Signaling or signal transduction is a process which involves binding of extracellular 
signaling molecules (a ligand or growth factors) to its specific receptors and turning on a 
specific cellular response. Several classes of intracellular signaling pathways exist: 
MAPK/ERK pathway, Hedgehog pathway, JAK/STAT (Janus kinase-signal transducer 
and activator of transcription) pathway and cAMP (cyclic Adenosine monophosphate) 
dependent pathway. Cellular functions are generally mediated by direct modifications of the 
key molecules or signaling complexes which lead to changes in gene expression.  
Phosphorylation is one of the common modes of protein modifications found in most 
signaling pathways. This process involves addition of a phosphate (PO4) group to a 
protein, which mainly occurs through serine (Ser), threonine (Thr) and tyrosine (Tyr) 
residues. Protein kinases are responsible for transferring a terminal phosphate (PO4) of 
ATP to a hydroxyl group (OH) of a protein, whereas, phosphatases can reverse the 
phosphorylation process (Cozzone, 1988) .  
 
1.3.1 Signaling Pathways and Cancer 
There are several signaling pathways that play a key role in controlling cell growth and 
cellular metabolism in response to growth factor stimulation. This is a tightly regulated 
process and any defect or alterations in the intracellular signaling pathways may lead to 
cancers (Braun et al., 2011). For example, mammalian target of rapamycin complex 1 
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(mTORC1) promotes glutamine metabolism in the cancer cells by indirectly regulating 
the activity of glutamate dehydrogenase (Durán et al., 2012; Sancak et al., 2008). In 
addition, increasing evidences suggest that different oncogenic transcription factors 
upregulate metabolic enzymes, which results in altered metabolism and cancer (Kim et 
al., 2006; Vogelstein and Kinzler, 2004). Three major transcription factors such as HIF 
(hypoxia-inducible factor 1), Myc, and Srebp-1 are the key regulators of energy 
metabolism and are often found to be deregulated in most cancers. HIFs are responsible 
for controlling glucose metabolism (Kim et al., 2006; Kondo et al., 2002) c-Myc, alters 
both glucose metabolism and glutaminolysis (Gao et al., 2009; Wise et al., 2008), and 
Srebp-1 increases lipid metabolism in the cancer cells (Figure 6). Taken together, 
targeting the altered signaling pathways in the cancer cells represents a new approach for 







Figure 6: Oncogenic signaling pathways that controls cancer metabolism. Different 
oncogenes and tumor suppressor genes are illustrated in the figure; which regulates 
specific enzymes involved in cancer metabolism. This signaling pathway is regulated by 
the post translational modifications (phosphorylation and proteolysis) are shown. Directly 
(unbroken lines) and indirectly (unbroken lines) interacting proteins are illustrated. This 
figure is adapted from  (Shaw and Cantley, 2012). 
 
1.3.2 Oncogenic Signaling Pathways and Glutaminolysis   
It was recently shown that the activity of glutaminase could be regulated by many 
oncogenes that are linked with cell metabolism (Figure 7). The oncogenic transcription 
factor, Myc, plays a crucial role in coordinating glutamine metabolism and proliferation 
(DeBerardinis et al., 2008). Previously, the unregulated Myc was noticed in many human 
tumors such as colon, lung, and brain (Nau et al., 1985; Taub et al., 1982). In a search of 
Myc-regulated mitochondrial proteins, Gao et al., have identified that glutaminase is 
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unregulated in the cells which express c-Myc (Gao et al., 2009). Interestingly, it has been 
demonstrated that the c-Myc stimulates the expression of glutaminase through repressing 
miR-23a and miR-23b in human lymphoma and prostate cancer cells. Indeed, these cells 
are very sensitive to glutamine withdrawal or glutaminase knockdown, which in turn 
results in loss of cell growth and survival (Gao et al., 2009). In addition, c-Myc has been 
shown to be involved in controlling many glycolytic enzymes that promote glucose 
metabolism and cancers (Kim et al., 2006; Osthus et al., 2000).  
 
One recent study has shown that the elevated activity of glutaminase could promote 
glutamine metabolism not only in transformed fibroblasts but also in the human breast 
cancer cells (Wang et al., 2010). It has been found that glutaminase activity was up-
regulated by downstream of Rho GTPase signaling in an NF-kB (Nuclear Factor kappa-
light-chain-enhancer of activated B cells) dependant manner (Figure 7). Rho GTPases are 
well studied oncogenes and are commonly activated in wide range of tumors such as 
colon, lung, breast cancers, pancreatic, and urinary tract tumors (Fritz et al., 1999; 
Schnelzer et al., 2000; Suwa et al., 1998). Further, a study links the glutaminolysis 
pathway with the cell cycle/cancer progression, through the observation that glutaminase 
could be targeted by the ubiquitin ligase (APC/C) (Colombo et al., 2010). Taking into all 







Figure 7: Schematic representation of the oncogenic regulation of glutaminase in the 
glutaminolysis pathway. Oncogene, Myc regulates glutaminase through miR-23a/b 
dependent manner; whereas Rho GTPase controls glutaminase in an NF-kB-dependent 
manner. This figure is adapted from  (Lu et al., 2010). 
   
 
1.3.3 Overview of the Ras/MAPK Signaling Pathways 
The Mitogen Activated Protein Kinase (MAPK) pathway has been found in most 
eukaryotic organisms and is highly conserved. This pathway can be activated by 
molecules such as mitogens, cytokines, and also by some physical stressors such as UV 
radiation, osmotic shock and heat. The MAPK module has three protein kinases which 
act sequentially, it including, MAP kinase kinase kinase (MAPKKK or MEKK), MAP 
kinase kinase (MAPKK or MEK) and MAP kinase (MAPK). This pathway is known to 
control diverse cellular functions such as, cell proliferation, differentiation, cell cycle 
progression, gene expression, embryogenesis, cellular metabolism, and apoptosis 
(Dhillon et al., 2007; Pearson et al., 2001). The MAPK pathway is further subdivided into 
four different groups: ERK/MAPK, JNK/SAPK, p38 and ERK5 pathways.   
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1.3.4 ERK/MAPK Pathway 
Receptor tyrosine kinases (RTKs) are the key regulators of cell signaling and are found to 
play a role in apoptosis, cell growth, proliferation and cancer progression (Zwick et al., 
2001). Binding of a growth factor on the extracellular domain of the RTK, induces 
dimerization and which inturn autophosphorylates tyrosine residues and results in the 
activation of RTK.  The activated RTK further triggers the downstream signaling 
pathways, for example ERK/MAPK kinase signaling cascade which has been shown in 
Figure 8.  The auto-phosphorylated tyrosine recruits Grb2 (adaptor protein). The guanine 
nucleotide exchange factor Son of Sevenless (SOS) in turn translocates to the membrane 
and associates with Grb2 to catalyze the activation of Ras (a small GTPase) by 
exchanging GDP to GTP. Activated Ras-GTP, further turns on a signaling cascade. Ras-
GTP directly binds and activates a protein kinase called Raf, (a serine/threonine kinase). 
This Raf subsequently phosphorylates either serine or theoronine residues of the MEK 
(also known as MAP kinase kinase). Consequently, the activated MEK then 







Figure 8: An overview of ERK/MAPK cascade. This pathway is commonly activated by 
growth factors (eg. TGFα). Activated ERKs regulates various transcription factors inside 
the nucleus, leading to changes in gene expression. The mutated form of B-Raf, Ras in 
the ERK/MAPK cascade often found in many human cancers. This figure is adapted from  
(Roberts and Der, 2007). 
 
 
Activated Erk then phosphorylates Ser/Thr-Pro motif of many protein substrates to 
control diverse cellular functions. In the RAS/RAF/MEK/ERK signaling pathway, Mek is 
a key protein kinase, which plays an important role in regulating cancer cell growth and 
proliferation. The deregulated activity of MEK is commonly found in wide range of 
human tumors, particularly, those that express mutant form of RAS and RAF oncogenes 
(Friday and Adjei, 2008; Roberts and Der, 2007). It is demonstrated from the preclinical 
studies that MEK inhibitors are found to be synergistic or additive when combined with 




In this thesis, we have shown that RAS/RAF/MEK/ERK module could act as a regulatory 
pathway to enhance the activity of glutaminase. These findings are described in detail in 
Chapter II.  
 
1.4 Current Molecular Targets 
From a therapeutic perspective, the effort to develop drugs that could starve the cancer 
cells by blocking their energy requirements are under development. Currently, there are 
several potential lead compounds that are undergoing preclinical development and some 
of them are in clinical trials (Jones and Schulze, 2012) (Table 1). These drugs specifically 
target the metabolic pathway enzymes (glycolysis, TCA, glutaminolysis, and fatty acid 
synthesis pathways) which appear to be responsible for feeding the cancer cell energy 
requirements. Targeting metabolism has the potential to offer an alternative to 
chemotherapy or radiotherapy and any other treatment regimes where these drugs 
selectively kill the cancer cell without affecting the normal cells. One striking example in 
this context is the development of the drug called dicholoro acetate (DCA). DCA is 
shown to shift the altered glucose metabolism that is found in the cancer cells. By 
inhibiting a key enzyme pyruvate dehydrogenase (PDK1), DCA was shown to prevent 
the pyruvate conversion to lactate, thus reversing the Warburg effect. More importantly, 
DCA was shown to effectively shrink the lung, colon cancers (Bonnet et al., 2007). 
Preliminary clinical trial results suggested that DCA is well tolerated by human patients 
























Table 1: List of potential compounds that target cancer metabolism. These compounds target metabolic enzymes that are responsible 
the altered metabolism and cancer formation. Details of compounds, their molecular targets and status are shown. Table adapted from 




In addition, several metabolic enzymes have been identified in recent studies as a target 
for small molecules includingIsocitrate dehydrogenase 1 (IDH1), hexokinase, Pyruvate 
kinase M2 (PKM2) and Glutaminase (GLS). A list of the potential compounds and their 
molecular targets is summarized in the table (Table 1). The glutaminase inhibitors 
BPTES and DON have also been proposed as potential anticancer drugs, which are 
currently in the early stage of clinical development (Table 1). Chapter II and Chapter III 
of this thesis report the structural basis of the inhibition mechanism of glutaminase by 
BPTES and DON respectively. 
 
1.5 Glutaminase: A key enzyme in glutaminolysis 
 
Glutaminase (EC number 3.5.1.2.) is an amidohydrolase enzyme which catalyzes the 




                    Glutamine                                                                                 Glutamate 
Figure 4: Reaction catalyzed by glutaminase.  
 
Mitochondrial glutaminase (GA) is the first enzyme in glutaminolysis, and through the 
subsequent enzymatic reactions, glutamine serves as a major substrate of TCA cycle 




1.5.1 Glutaminase Isoforms 
In humans, two major glutaminase isoforms have been described, kidney type 
glutaminase (KGA/GLS/GLS1) and Liver type glutaminase (LGA/GLS2). Both isoforms 
are encoded by two different but closely related genes. The Gls gene that codes for KGA 
isoform is located in chromosome 2 (Aledo et al., 2000). The Gls gene also encodes two 
different splice variants such as Glutaminase C (GAC) and Glutaminase M (GAM) 
isoforms, which are collectively referred as KGA (Elgadi et al., 1999). The LGA isoform 
encoded by Gls2 gene is located in chromosome 12 (Aledo et al., 2000). Though, both 
isoforms of human glutaminase were predicted to have high sequence homology (KGA 
vs LGA is 63% sequence identity), they are found to have difference in their tissue 
distribution, kinetic and biochemical properties (Curthoys and Watford, 1995; Elgadi et 
al., 1999).  
 
The KGA isoform is highly expressed in kidney, brain, intestine, fetal liver, lymphocytes, 
and in many tumors (Curthoys and Watford, 1995). In the kidney, KGA is responsible for 
the renal ammoniagenesis (Curthoys and Godfrey, 1976; Lupianez et al., 1981); whereas 
KGA is the major producer of glutamate, an excitatory neurotransmitter of the central 
nervous system in the brain (CNS) (Yu et al., 1984). Glutaminase C (GAC) is the 
alternatively spliced isoform of the KGA (GAC vs KGA is 83% sequence identity), 
mainly expressed in heart and pancreas but not in liver (Elgadi et al., 1999; Porter et al., 
2002). Similarly, the other alternatively spliced variant of the KGA, namely hGAM, is 
found only in the heart and skeletal muscle (Elgadi et al., 1999). The expression of Liver 
type glutaminase (LGA) was originally thought to be only in liver (Elgadi et al., 1999). 
24 
 
Nevertheless, recent studies have demonstrated its expression in extrahepatic tissues such 
as brain, pancreas and cancers (Gómez-Fabre et al., 2000; Pérez-Gómez et al., 2005; 
Turner and McGivan, 2003) (Table 2).  
 
Type Genetic Structure 
Cellular 
Location 
Tissue Expresson References 





(Aledo et al., 2000; 
Curthoys and 
Watford, 1995; 










(Elgadi et al., 1999; 
Porter et al., 2002; 
Shapiro et al., 
1985) 
hGAC 
 KGA isoform: 
Unique 3’  tail 





Kidney, Lung, Brain 
(Elgadi et al., 1999; 
Porter et al., 2002) 
 
Table 2: Glutaminase isoforms. Different isoforms of human glutaminase, their location, 
and tissue expression are given. This table is adapted from (Erdmann et al., 2006). 
 
The important difference between KGA and LGA isoform is their mode of inhibition and 
activation mechanism. KGA is activated by phosphate and inhibited by glutamate (the 
product), whereas LGA is less dependent on phosphate for its activation and not inhibited 
by glutamate (Curthoys and Godfrey, 1976). The activation of recombinant KGA 
requires inorganic phosphate that converts the inactive dimeric form to active tetrameric 
or oligomeric form (Godfrey et al., 1977; Morehouse and Curthoys, 1981). Besides 
phosphate, acetyl-coA, and ADP were shown to stimulate the activity of KGA (Kvamme 




1.5.2 Sequence Analysis of Glutaminase 
The isoforms of human glutaminase contains distinct combination of signature motifs and 
functional domains, and is often referred to as “multifaceted protein” (Márquez et al., 
2006) (Figure 10 and Figure 11). The glutaminase isoforms KGA and GAC have high 
sequence homology in the N-terminal region of the protein, and only 12% sequence 
identity was found in the C-terminals. Starting from N-terminal, the first 16 amino acids 
of all three isoforms (KGA, GAC and LGA) have conserved sequence, known as transit 
peptides. This is shown to be responsible for the localization of enzyme into 
mitochondria (Gómez-Fabre et al., 2000).  In addition, the nuclear receptor targeting box 
(NR box) has been found in all three glutaminase isoforms, which specifically interacts 




Figure 10: Domain architecture of human KGA. The signature domains and functional 
motifs of KGA are illustrated in the figure. KGA contains Signal peptide (amino acids 1-
16), nuclear targeting box (amino acids 138-144), glutaminase domain (244-530), 
ankyrin repeats (amino acids 556-656), and KEN box (amino acids 656-669) 
(Thangavelu et al., 2012).  
 
Human KGA has NR box with the sequence of LDDLL on the N-terminal residues from 
138-144 whereas LGA has the similar motif from 72-76. Pfam data base suggests the 
presence of glutaminase domain (aa 244-530) in KGA and residues 177–463 form 
glutaminase domain in LGA (Finn et al., 2010).  The C-terminal of glutaminase has a 





KGA             MMRLRGSGMLRDLLLRSPAGVSATLRRAQPLVTLCRRPRGGGRPAAGPAAAARLHPWWGG 60 
GAC             MMRLRGSGMLRDLLLRSPAGVSATLRRAQPLVTLCRRPRGGGRPAAGPAAAARLHPWWGG 60 
LGA             --------------MRSMKALQKALSRAG---SHCGR----------------------- 20 
                              :**  .:. :* **    : * *                        
 
KGA             GGWPAEPLARGLSSSPSEILQELGKGSTHPQPGVSPPAAPAAPGPKDGPGETDAFGNSEG 120 
GAC             GGWPAEPLARGLSSSPSEILQELGKGSTHPQPGVSPPAAPAAPGPKDGPGETDAFGNSEG 120 
LGA             GGWGHP------SRSP-----LLGGGVRHH---LSEAAAQGRETPHSHQPQHQDHDSSE- 65 
                ***         * **      ** *  *    :* .** .   *:.   : : ...**  
 
KGA             KELVASGENKIKQGLLPSLEDLLFYTIAEGQEKIPVHKFITALKSTGLRTSDPRLKECMD 180 
GAC             KELVASGENKIKQGLLPSLEDLLFYTIAEGQEKIPVHKFITALKSTGLRTSDPRLKECMD 180 
LGA             ------------SGMLSRLGDLLFYTIAEGQERIPIHKFTTALKATGLQTSDPRLRDCMS 113 
                            .*:*. * ************:**:*** ****:***:******::**. 
 
KGA             MLRLTLQTTSDGVMLDKDLFKKCVQSNIVLLTQAFRRKFVIPDFMSFTSHIDELYESAKK 240 
GAC             MLRLTLQTTSDGVMLDKDLFKKCVQSNIVLLTQAFRRKFVIPDFMSFTSHIDELYESAKK 240 
LGA             EMHRVVQESSSGGLLDRDLFRKCVSSNIVLLTQAFRKKFVIPDFEEFTGHVDRIFEDVKE 173 
                 :: .:* :*.* :**:***:***.***********:******* .**.*:*.::*..*: 
 
KGA             QSGGKVADYIPQLAKFSPDLWGVSVCTVDGQRHSTGDTKVPFCLQSCVKPLKYAIAVNDL 300 
GAC             QSGGKVADYIPQLAKFSPDLWGVSVCTVDGQRHSTGDTKVPFCLQSCVKPLKYAIAVNDL 300 
LGA             LTGGKVAAYIPQLAKSNPDLWGVSLCTVDGQRHSVGHTKIPFCLQSCVKPLTYAISISTL 233 
                 :***** ******* .*******:*********.*.**:***********.***::. * 
 
KGA             GTEYVHRYVGKEPSGLRFNKLFLNEDDKPHNPMVNAGAIVVTSLIKQGVNNAEKFDYVMQ 360 
GAC             GTEYVHRYVGKEPSGLRFNKLFLNEDDKPHNPMVNAGAIVVTSLIKQGVNNAEKFDYVMQ 360 
LGA             GTDYVHKFVGKEPSGLRYNKLSLNEEGIPHNPMVNAGAIVVSSLIKMDCNKAEKFDFVLQ 293 
                **:***::*********:*** ***:. *************:**** . *:*****:*:* 
 
KGA             FLNKMAGNEYVGFSNATFQSERESGDRNFAIGYYLKEKKCFPEGTDMVGILDFYFQLCSI 420 
GAC             FLNKMAGNEYVGFSNATFQSERESGDRNFAIGYYLKEKKCFPEGTDMVGILDFYFQLCSI 420 
LGA             YLNKMAGNEYMGFSNATFQSEKETGDRNYAIGYYLKEKKCFPKGVDMMAALDLYFQLCSV 353 
                :*********:**********:*:****:*************:*.**:. **:******: 
 
KGA             EVTCESASVMAATLANGGFCPITGERVLSPEAVRNTLSLMHSCGMYDFSGQFAFHVGLPA 480 
GAC             EVTCESASVMAATLANGGFCPITGERVLSPEAVRNTLSLMHSCGMYDFSGQFAFHVGLPA 480 
LGA             EVTCESGSVMAATLANGGICPITGESVLSAEAVRNTLSLMHSCGMYDFSGQFAFHVGLPA 413 
                ******.***********:****** ***.****************************** 
 
KGA             KSGVAGGILLVVPNVMGMMCWSPPLDKMGNSVKGIHFCHDLVSLCNFHNYDNLRHFAKKL 540 
GAC             KSGVAGGILLVVPNVMGMMCWSPPLDKMGNSVKGIHFCHDLVSLCNFHNYDNLRHFAKKL 540 
LGA             KSAVSGAILLVVPNVMGMMCLSPPLDKLGNSHRGTSFCQKLVSLFNFHNYDNLRHCARKL 473 
                **.*:*.************* ******:*** :*  **:.**** ********** *:** 
 
KGA             DPRREGGDQRVKSVINLLFAAYTGDVSALRRFALSAMDMEQRDYDSRTALHVAAAEGHVE 600 
GAC             DPRREGGDQ---------------------RHSFGPLDYES--LQQELALKETVWK---- 573 
LGA             DPRREGAEIRNKTVVNLLFAAYSGDVSALRRFALSAMDMEQKDYDSRTALHVAAAEGHIE 533 
                ******.:                      *.::..:* *.   :.. **: :. :     
 
KGA             VVKFLLEACKVNPFPKDRWNNTPMDEALHFGHHDVFKILQEYQVQYTPQGDSDNGKENQT 660 
GAC             ---------KVSPESNEDISTTVVYRMESLGEKS-------------------------- 598 
LGA             VVKFLIEACKVNPFAKDRWGNIPLDDAVQFNHLEVVKLLQDYQDSYTLSETQAEAAAEAL 593 
                         **.* .::  ..  :     :.. .                           
 
KGA             VHKNLDGLL 669 
GAC             --------- 





Figure 11: Sequence-based analysis of human glutaminase isoforms. The sequence 
alignments of three isoforms KGA, GAC and LGA was performed by ClustalW 





The ankyrin repeats has approximately 30 amino acids and found in several signaling 
proteins whose functions include transcriptional initiation, cell cycle regulation, 
cytoskeleton, and signal transducers (Li et al., 2006). According to the Pfam database, 
KGA contains three ankyrin repeats, whereas LGA contains two ankyrin repeats. The 
exact function of ankyrin repeats in human glutaminase is still not known. Interestingly, 
KGA has a KEN box in the C-terminal end that is specifically targeted by ubiqutin ligase 
APC/C during cell-cycle progression (Colombo et al., 2011). On the other hand, LGA 
contains a unique motif EMSV in the C-terminal end which specifically interacts with 
PDZ domain containing proteins (Olalla et al., 2002). 
 
1.5.3 Structure of Glutaminase 
Glutaminase have been reported to present in many organisms including, bacteria, yeast, 
fungi and mammals but not found in thermophiles, archaea and plants (Yoshimune et al., 
2009). A PSI-BLAST search with the KGA sequence suggested the presence of over 50 
homologs from various species and all of them  belong to the glutaminase superfamily. 
Besides, a BLAST search with the KGA sequence against protein data bank (PDB) 
showed several homologs in the PDB. The closest homolog includes microbial 
glutaminase from Micrococcus luteus (PDB: 1U60) and probable glutaminase from 
Geobacillus Kaustophilus (PDB: 2PBY), both shares 38% sequence identity with KGA. 
The monomeric structure of probable glutaminase YbgJ (Geobacillus Kaustophilus ) 
consists of two domains; α/β/α sandwich and associated α-helical domain. The crystal 
structure of YbgJ revealed the presence of five anti parallel β strands (β1, β2, β8,  β9, and 
β10) that are surrounded by several α helices and loops (Figure 12).  Furthermore, YbgJ 
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structure revealed the presence of β lactamase motif 1 (Ser- X-X-Lys), where Ser74 was 
identified to act as a catalytic nucleophile (Brown et al., 2006). The sequence alignment 
of KGA with the selected homologs from E. coli and Micrococcus luteus suggested the  
presence of β-lactamase-like motif in  KGA.  
                                  
Figure 12. Crystal structure of E.Coli glutaminase. The secondary structure elements 
such as α-helices (cyan), β-strands (magenta), loops (magenta) are shown. The location of 
the active site is  indicated by black arrow. This figure adapted from (Yoshimune et al 
2009). 
1.5.4 Binding Partners of Glutaminase 
A recent study by Buschdorf et al., has identified Caytaxin or BNIP-H (brain-specific 
BNIP-2-homology protein) as an interacting partner of KGA (Buschdorf et al., 2006). 
Interestingly, the C-terminal part of the BNIP-H contains a novel protein-protein 
interaction domain, called the BCH domain (BNIP-2 and Cdc42GAP Homology) that 
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directly interacts with KGA. The BCH domain approximately contains 145 residues and 
was initially identified in two proteins; BNIP-2 and Cdc42GAP (Low et al., 2000). It has 
been established that the BCH domain in several proteins regulates a wide range of 
cellular functions including cell apoptosis, cell elongation, migration, rounding and Ras-




Figure 13: Schematic representation showing the direct interaction of Caytaxin and 
glutaminase (KGA). (A) The C-terminal caytaxin contains a novel domain called BCH 
that directly binds and inhibits the activity of KGA, (B) thereby it reduces the steady-
state level of glutamate (Buschdorf et al., 2006).  
 
 
Caytaxin or BNIP-H is encoded by gene ATCAY and mutation in this gene has been 
implicated in human Cayman cerebellar ataxia (Bomar et al., 2003). The BCH domain of 
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Caytaxin, has been found to directly inhibit the activity of KGA; thereby reducing the 
level of glutamate (Figure 13). Furthermore, it was also found that KGA interaction is 
mediated via atleast two different region of the BCH domain; (aa 191-235) and (aa 288-
331) (Buschdorf et al., 2006). The other isoform LGA is known to directly interact with 
PDZ domain containing proteins such as SNT and GIP (Banerjee et al., 2008; Olalla et 
al., 2008).  
 
1.5.5 Glutaminase in Neurodegenerative Diseases 
In the brain, the role of KGA is briefly described in glutamine-glutamate cycle (Masson 
et al., 2006). Once glutamine is released from the glial cell, mitochondria glutaminase 
(KGA) converts glutamine into glutamate. Upon nerve stimuli, glutamate is released 
from presynaptic terminals and activates glutamate receptors to exert its physiological 
functions. Subsequently, glutamate is converted back into glutamine by glutamine 
synthetase. The glutamine-glutamate cycle is an essential event to maintain low level of 
glutamate in the synapse, avoiding glutamate accumulation and its associated glutamate 
excitotoxicity (Choi and Rothman, 1990). Glutamate excitotoxicity is a principal 
mediator for several neurological disorders including seizures, stroke, trauma, multiple 
sclerosis, and schizophrenia. The excess activity of mitochondrial glutaminase (KGA 
isoform) was found to be associated with stroke and schizophrenia,
 
due to the KGA-
mediated glutamate excitotoxicity (Masson et al., 2006; Newcomb et al., 1997). In 
multiple sclerosis (MS) animal model studies, the activated microglia has been shown to 
play a key role in the generation of excessive glutamate through the release of KGA 
(Shijie et al., 2009). Release of KGA from the HIV-1 infected mononuclear phagocytes 
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was noticed to induce glutamate toxicity that leads to Human immunodeficiency virus 
Associated Dementia (HAD) (Figure 14). Consequently, inhibition of KGA activity by 
small molecule inhibitors resulted in decreased level of glutamate in the cell (Erdmann et 
al., 2009; Erdmann et al., 2006). Taken together, these findings indicate that KGA has 
been considered as a potential target for the development drugs towards several 
neurological conditions.  
                     
 
 
Figure 14: A schematic model for glutaminase activity in HAD. Glutaminase (KGA 
isoform) releases from the infected microglia converts glutamine to glutamate. Over 
stimulation of glutamate receptor NMDAR by glutamate, leads to neuron death. This 







1.6 Glutaminase inhibitors  
 
Numerous studies suggest that KGA is a potential therapeutic target for many cancers 
includes lymphoma, prostate, brain and kidney cancers (Erickson and Cerione, 2010; Gao 
et al., 2009; Seltzer et al., 2010; Wang et al., 2010). In this regard, small-molecules 
targeting this enzyme could potentially be used to arrest glutamine-dependent cell growth 
and tumor formation. To date, few small molecule inhibitor of glutaminase have been 
reported. The active site inhibitor that includes 6-Diazo-5-Oxo-l-Norleucine (DON) and 
L-2-amino-4-oxo-5-chloropentanoic acid (CK) are glutamine and glutamate analogs 




Figure 5: Chemical structures of glutamine and glutamate analogs. 6-Diazo-5-Oxo-l 
Norleucine (DON) and L-2-amino-4-oxo-5-chloropentanoic acid (CK) are active site 




The inhibitor DON is non-specific to human glutaminase, because it not only inhibits 
glutaminase but also is shown to inhibit other glutamine or glutamate utilizing enzymes 
such as glutamine amidotransferase and glutamine synthetase (Barclay and Phillipps, 
1966; Ortlund et al., 2000; Pinkus, 1977). The potential anticancer activity of DON has 
been studied in different animal models, however, it has not progressed to clinical trials 
due to the toxicity concerns (Ahluwalia et al., 1990; Ovejera et al., 1979). 
       
                                                 
 
Figure 6: Chemical structure of glutaminase–allosteric inhibitors: BPTES [bis-2-(5-
phenylacetamido-1,2,4-thiadiazol-2-yl) ethyl sulfide] and compound 968, [-(3-bromo-4 





In recent years, much effort has been taken to develop potent and selective inhibitors of 
glutaminase with better therapeutic efficacy towards human cancers. Recently, BPTES 
[bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl) ethyl sulfide] (Figure 16) was identified 
as a potent and selective inhibitor for KGA (Robinson et al., 2007). This compound was 
originally thought to have therapeutic potential towards the neurological disorders where 
it reduces the glutamate level through the inhibition of glutaminase in cultured neurons. 
However, recent studies highlighted BPTES as a cancer metabolism inhibitor, as it 
inhibits glutaminase that feeds the cancer cells with glutamine. Strikingly, BPTES was 
recently shown to be effective against glioblastoma tumors (low-grade gliomas and 
secondary glioblastomas), by indirectly reducing the activity of R132H mutant form of 
isocitrate dehydrogenase-1 (IDH1) (Figure 17). The enzyme IDH1 usually converts α-
ketoglutarate (α-KG) into isocitrate. However, R132H mutant form of IDH1 is commonly 
found in the brain cancers (glioblastoma cells) that unusually converts α-ketoglutarate (α-
KG) into 2-hydroxyglutaric acid (2-HG), an “onco-metabolite” which supports 
tumorigenesis (Dang et al., 2010). By inhibiting glutaminase, BPTES reduces the 
glutamate derived α-ketoglutarate levels and delays the growth of cells harboring IDH 
mutations (Seltzer et al., 2010).  
 
Furthermore in animal model studies, BPTES has proven to be effective in delaying 
tumor xenograft growth (Keibler et al., 2012). In addition, BPTES is known to be the 
most potent among all the inhibitors studied so far (DeLaBarre et al., 2011; Hartwick and 
Curthoys, 2011; Thangavelu et al., 2012). The selectivity and high potency of BPTES 
against KGA makes this inhibitor an ideal candidate for the therapeutics and notably, this 
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compound has entered in preclinical trials (Garber, 2010; Jones and Schulze, 2012). 
Similarly, Wang et al., identified a compound 5-(3-bromo-4 (dimethylamino) phenyl)-
2,2-dimethyl-2,3,5,6-tetrahydrobenzo[ a] phenanthridin-4(1H)-one, named 968 as an 
allosteric inhibitor of glutaminase. This compound has been shown to inhibits 
recombinant GAC  invitro, and as well blocks the growth of tumors in mouse xenograft 
models invivo (Wang et al., 2010). 
 
 
                               
 
Figure 7: BPTES inhibits IDH1 mutant isoform indirectly. The pathway shows the 
production of 2-HG (an oncometabolite) by IDH1 mutant isoform. BPTES specifically 
inhibits of GLS/KGA in glioblastoma cells and it reduces the glutamate derived α-
ketoglutarate level, a substrate of tumor specific IDH1 mutant isoform. This figure is 






The major objective of this thesis is to understand the structural and functional basis of 
human kidney type glutaminase (KGA) and its implications in arresting cancer cell 
metabolism. This will be accomplished through the combination of structural, 
biochemical, molecular, and cell-based studies. Our objectives will be achieved through 
the following studies:  
(a) To study the structure based inhibition mechanism of KGA by small molecule 
inhibitors BPTES and DON. 
(b) To study the regulatory role of KGA in the Raf-Mek-Erk signaling pathway in 
cancer metabolism. 
(c) To identify the growth factors which are connected to Raf-Mek-Erk signaling 
pathway in regulating KGA activity. 
(d) To validate the effect of BPTES in inhibiting cancer cell growth and proliferation 
using different cancer cell lines which express full length KGA. 
(e) To study the functional importance of inhibitors-interacting residues and also to 
explore the specificity of BPTES towards KGA.  
    (h)  To establish a synergistic inhibitory mechanism between both KGA and Raf-Mek-



























Structural basis for the allosteric 
inhibitory mechanism of human kidney 
type glutaminase (KGA) and its 
regulation by Raf-Mek-Erk signaling in 













The Warburg effect in cancer biology describes the tendency of cancer cells to take up 
more glucose than most normal cells despite the availability of oxygen (DeBerardinis et al., 
2008; WARBURG, 1956a). In addition to altered glucose metabolism, glutaminolysis 
(catabolism of glutamine to ATP and lactate) is another hallmark of cancer cells 
(DeBerardinis et al., 2008; Reitzer et al., 1979). In glutaminolysis, mitochondrial 
glutaminase (GA) catalyzes the conversion of glutamine to glutamate (Curthoys and 
Watford, 1995),
 
which is further catabolized in the Krebs cycle for the production of ATP, 
nucleotides, certain amino acids, lipids and glutathione (DeBerardinis et al., 2008; Wise et 
al., 2008) .  
 
Humans express two glutaminase isoforms, KGA (Kidney-type) and LGA (Liver-type) 
from two closely related genes (Aledo et al., 2000). Although KGA is important for 
promoting growth, nothing is known about the precise mechanism of its activation or 
inhibition and how its functions are regulated under physiological or patho-physiological 
conditions. Inhibition of rat KGA activity by antisense mRNA results in decreased 
growth and tumourigenicity of Ehrlich ascites tumor cells (Lobo et al., 2000), reduced 
level of glutathione, and induced apoptosis (Lora et al., 2004), whereas Myc, an 
oncogenic transcription factor, stimulates KGA expression and glutamine metabolism 
(Wise et al., 2008). Interestingly, direct suppression of miR23a and miR23b (Gao et al., 
2009) or activation of TGF (Andratsch et al., 2007) enhances KGA expression. Similarly, 
Rho GTPase that controls cytoskeleton and cell division also up-regulates KGA 
expression in an NF-kB dependent manner (Wang et al., 2010). In addition, KGA is a 
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substrate for the ubiquitin ligase anaphase-promoting complex/cyclosome (APC/C)-
Cdh1, linking glutaminolysis to cell cycle progression (Colombo et al., 2010). In 
comparison, function and regulation of LGA is not well studied although it was recently 
shown to be linked to p53 pathway (Hu et al., 2010; Suzuki et al., 2010). Although 
intense efforts are being made to develop a specific KGA inhibitor such as BPTES [bis-2-
(5-phenylacetamido-1, 2, 4-thiadiazol-2-yl) ethyl sulfide] (Robinson et al., 2007), its 
mechanism of inhibition and selectivity is not yet understood. Equally important is to 
understand how KGA function is regulated in normal and cancer cells so that a better 
treatment strategy can be considered. 
 
The previous crystal structures of microbial (Mglu) and Escherichia coli glutaminases 
show a conserved catalytic domain of KGA (Brown et al., 2008; Yoshimune et al., 2010). 
However, detailed structural information and regulation are not available for human 
glutaminases especially the KGA, and this has hindered our strategies to develop 
inhibitors. In this chapter, we report the crystal structure of the catalytic domain of human 
apo KGA and its complexes with substrate (L-glutamine), product (L-glutamate), 
BPTES, and its derived inhibitors. Further, Raf-Mek-Erk module is identified as the 
regulator of KGA activity. Although BPTES is not recognized in the active site, its 
binding confers a drastic conformational change of a key loop (Glu312-Pro329), which is 
essential in stabilizing the catalytic pocket. Significantly, EGF (epidermal growth factor) 
activates KGA activity, which can be abolished by the kinase-dead, dominant negative 
mutants of Mek2 (Mek2-K101A) or its upstream activator Raf-1 (Raf-1-K375M), which 
are the kinase components of the growth-promoting Ras-Mek2-Erk signaling node. 
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Furthermore, co-expression of phosphatase PP2A and treatment with Mek-specific 
inhibitor or alkaline phosphatase all abolished enhanced KGA activity inside the cells and 
in vitro, indicating that stimulation of KGA is phosphorylation-dependent. Our results 
therefore provide novel mechanistic insights into KGA inhibition by BPTES and its novel 
regulation by EGF-mediated Raf/Mek/Erk module in cell growth and possibly cancer 
manifestation. This paves the way for developing more specific therapeutic inhibitors for 
KGA in glutamine-addicted cancers.  
 
2.2 Materials and Methods 
2.2.1 Cloning, Protein Expression, and Purification 
The human KGA consists of 669 amino acids. We refer to Ile221-Leu533 as the catalytic 
domain of KGA (cKGA) (Figure 11). The cKGA was cloned into a pET-28(b) vector 
fusion with N-terminal His tag (pNICBsa4 cleavable with tobacco etch virus (TEV) 
protease, and the protein was expressed in Escherichia coli BL21 (DE3)-RIL-Codon plus 
cells grown in 6 L LB broth medium. Cells were sonicated in lysis buffer [50 mM Hepes 
(pH 7.5), 500 mM NaCl, 5 mM imidazole, 10% glycerol, 1 mM DTT, 0.1% (vol/vol) 
Triton X-100, and one tablet of complete protease inhibitor mixture] (Roche Diagnostics) 
and further lysed by French press. The soluble fraction was passed on to a Ni-NTA 
affinity column (Qiagen), and the bound protein was eluted with 500 mM imidazole. The 
His6 tag was cleaved with TEV protease at 4 °C for 20 h. The protein was further purified 
by gel filtration column (Superdex-200; GE Healthcare) and then concentrated to 20 
mg/mL in a buffer containing 20 mM Hepes (pH 7.5), 200 mM NaCl, 10% glycerol, and 
3 mM DTT. The recombinant cKGA mutants were generated by site-directed 
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mutagenesis on the pET-28(b)-cKGA plasmid using the KAPA polymerase site-directed 
mutagenesis kit (Kapa Bio-systems) (Table 4). All cKGA mutants were expressed and 
purified using similar protocol as described above. 
 
2.2.2 Inhibitor Synthesis  
All inhibitors (1–5) were synthesized by following the reported procedure (Newcomb, 
2002). The diamino compounds (2–4) were prepared by refluxing thiosemicarbazide (5 
mmol) and appropriate dicarboxylic acid (15 mmol) in the presence of POCl3 for 2 h. 
Upon cooling the reaction mixture was poured over 200 g of ice. The turbid suspension 
was filtered, and the filtrate was basified with potassium carbonate to precipitate the 
product. The precipitate was filtered and washed with plenty of water and dried at 
vacuum to afford the target amines in moderate yield of ≈50%. The amide derivatives (1 
and 5) were synthesized by condensing the diamino compound (1) (1 mmol) and 
corresponding acid chloride (3 mmol) in dry pyridine for 12 h. After cooling, the reaction 
mixture was poured into 50 mL of methanol. The precipitated product was filtered and 
washed with plenty of methanol to afford the target compounds.  
 
General procedure for the synthesis of diamino bis-thiazole derivatives (1–3): 
thiosemicarbazide (0.45 g, 5 mmol) and appropriate dicarboxylic acid (15 mmol) were 
refluxed in 10 mL of POCl3 for 2 h. Upon cooling the reaction mixture was poured over 
200 g of ice. The turbid suspension was filtered, and the filtrate was basified with 
potassium carbonate to precipitate the product. The precipitate was filtered and washed 





3,3′-thiodipropionic acid (5.67 g). 0.75 g of product (yield = 53%)  
1,5-(5-amino-1,3,4-thiadiazol-2yl)pentane (2): 
Pentane-1,5-dicarboxylic acid (2.4 g). 0.6 g of product (yield = 45%)  
1,5-(5-amino-1,3,4-thiadiazol-2yl]butane (3):  
1,6-hexanedioic acid (2.2 g). 0.5 g of product (yield = 40%) 
 
General procedure for amide synthesis (4 and 5): diamino compound 1 (1 mmol) and 
corresponding acid chloride (3 mmol) were refluxed in 10 mL of dry pyridine for 12 h. 
Upon cooling, the reaction mixture was poured into 50 mL of methanol. The precipitated 
product was filtered and washed with plenty of methanol to afford the target compound. 
 
Bis-2′-[5- (phenylacetamido)-1,3,4-thiazol-2-yl]ethylsulfide (4): 
Phenyl acetyl chloride (0.45 g). 0.3 g of product (yield = 57%) 
Bis-2′-[5-(3,4,5-trimethoxybenzamido)-1,3,4-thiazol-2-yl]ethyl sulfide (5): 
3,4,5-trimethoxybenzoyl chloride (0.69 g). 0.28 g of product (yield = 41%) 
 
 
Inhibitors were synthesized in collaboration with A/P Valiyaveettil Suresh, Department 






2.2.3 Glutaminase Assay 
Glutaminase assay was performed using a two step assay described previously (Kenny et 
al., 2003). Briefly, 10 μL of wild-type cKGA or cKGA mutant was incubated separately 
with 10 μL of first assay mix [20 mM glutamine, 50 mM Tris·acetate (pH 8.6), 80–150 
mM phosphate, and 0.2 mM EDTA] at 37 °C for 10 min, and the reaction was quenched 
with adding 2 μL of 3 M HCl. Subsequently 200 μL of the second assay mix [2.2 U 
glutamate dehydrogenase, 80 mM Tris·acetate (pH 9.4), 200 mM hydrazine, 0.25 mM 
ADP, and 2 mM nicotinamide adenine dinucleotide] was added and incubated for 30 min 
at room temperature. The absorbance at 340 nm was recorded using a microplate reader 
(SpectraMax 340; Molecular Devices). Compounds were prepared as a 10-mM stock in 
100% (vol/vol) DMSO, and necessary controls were established. The IC50 values were 
calculated from the fitted regression equation using the-log plot (Graphpad prism). Each 
value represents the means ± SD of three independent experiments, each with at least 
three replicates. Statistical significance was analyzed using ANOVA and the Student-
Newman-Kuels multiple range test (StatsDirect). Data are means ± SD (P < 0.05) and 
expressed as fold increase over the control cells. 
 
2.2.4 Crystallization and Data collection 
Crystallization screening was carried out by hanging drop vapor diffusion methods at 20 
°C using crystallization screens from Hampton Research (Aliso Viejo, CA, USA) and 
Jena Bioscience screens (Jena, Germany). apo cKGA crystals were grown in 0.1 M Bis-
Tris propane (pH 7.0), 1.7 M LiSO4, and 5% DMSO. cKGA-L-glutamine complex 
crystals were obtained by adding 10 mM L-glutamine with cKGA in 0.1 M Hepes Na 
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(pH 7.5), 2% PEG 400, and 2.1 M (NH4)2SO4. cKGA-L-glutamate complex crystals 
were obtained by adding 10 mM L-glutamate with cKGA in 0.1 M Bis-Tris propane (pH 
7.0), and 1.4 M LiSO4. The cKGA: BPTES complex was prepared by mixing cKGA (1 
mg/mL) with BPTES (inhibitor 1) to the final molar ratio of 1:7 and incubated at room 
temperature (23 °C) for 1 h. The complex was then concentrated to 22 mg/mL by 
centrifugation. Crystals of the cKGA: BPTES complex were grown in 0.1 M Bis-Tris 
propane (pH 7.0) and 1.8 M LiSO4. Similarly cKGA-inhibitors 2, 3, and 4 complexes 
were prepared and crystals obtained using a similar condition as BPTES complex. 
Crystals were cryoprotected in the reservoir solution with 20% glycerol and flash cooled 
in a N2 cold stream (100 K). Diffraction data were collected at the synchrotron beam lines 
[X12C, Brookhaven National Laboratory, New York, NY; BL13B1, National 
Synchrotron Radiation Research Center (NSRRC), Taiwan; and I911-3, MAX-lab, Lund, 
Sweden]. Data were processed and scaled using HKL2000 (Otwinowski Z and W., 1993) 
and XDS (Kabsch, 2010). The crystallographic data collection statistics are provided in 
Table 5. 
 
2.2.5 Structure Solution and Refinement 
We solved the crystal structure of glutaminase (cKGA)- L-glutamate complex [Protein 
Data Bank (PDB) code 3CZD] by molecular replacement with MolRep (Vagin and 
Teplyakov, 2010) using the coordinates of a homolog from Micrococcus luteus K-3 
(PDB 2DFW; 36% sequence identity with cKGA) as search model (Yoshimune et al., 
2010). This structure was refined using Refmac5 (Murshudov et al., 1997) and the 
models were examined and built in COOT (Emsley and Cowtan, 2004). Similarly the apo 
45 
 
cKGA and other complex structures are determined by molecular replacement with 
MolRep using the cKGA coordinates from cKGA–L-glutamate complex. All crystals 
were in space group I4122, and in all cases one apo/complex molecule of cKGA was 
observed in the asymmetric unit. The initial model with the electron density map was 
examined, and the model was fitted with COOT and subsequent refinement carried out 
with CNS (Brünger et al., 1998). Manual fitting of the inhibitor and refinements were 
carried out in O (Jones et al., 1991) and CNS programs respectively, with appropriate 
entries made in their respective libraries. Overall geometry of final models was analyzed 
by PROCHECK (Laskowski RA et al., 1993). The refinement statistics are provided in 
Table 5.  
 
2.2.6 Cell Culture, Growth Factor Stimulation, and Inhibitors Treatment. 
Human embryonic kidney epithelial 293T cells were maintained in RPMI-1640 
(HyClone) with 10% (vol/vol) FBS (from PPA, Cell Culture Company, Austria), 2 mM 
L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin (HyClone), whereas 
human breast epithelial cancer MCF7 cells were grown in high-glucose DMEM 
(HyClone). All cells were grown at 37 °C, 5% CO2. Confluent cells grown on six-well 
plates were transfected using Mirus (TransIT) with 2 μg of either vector plasmid or 
plasmids encoding wild-type KGA (full length), Raf-1, Mek2, or the various mutants as 
indicated. Twenty-four hours later, cells were treated with indicated doses of BPTES or 
DMSO for 48 h. For growth factor stimulation [using 100 ng/mL of EGF (Sigma), 20 μM 
of LPA (Sigma), 50 ng/mL of PDGF (Sigma), 1 ng/mL of TGF-β (R&D Systems), and 
10 ng/mL of basic FGF (bFGF; Promega)], the transfected cells were starved for 18 h and 
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stimulated with various growth factors and for the time indicated. Quiescent cells were 
treated with 20 μM of U0126 (Promega) and incubated at 37 °C for 30 min before growth 
factor stimulation. Cells were lysed with Hepes buffer [20 mM Hepes (pH 7.4), 150 mM 
NaCl, 1% Nonidet P-40, 20 mM glycerol-2-phosphate, 1 mM sodium orthovanadate, and 
20 mM sodium fluoride and protease inhibitors (Roche Applied Science)], and 260 μL of 
aliquots were used for the glutaminase assays as described. 
 
2.2.7 Phosphatase Treatment  
Beads with immunoprecipitated complex were resuspended with 50 μL of Tris buffer 
(100 mM NaCl, 50 mM Tris·HCl, 10 mM MgCl2, and 1 mM DTT; pH 7.9) and incubated 
with 20 U of calf intestine alkaline phosphatase (NEB) for 3 h at 37 °C. The beads were 
washed thrice with chilled Hepes buffer before glutaminase assay. 
 
2.2.8 Plasmids Construction and Site-Directed Mutagenesis 
The full length KGA cDNA is a generous gift from Norman P. Curthoys (Colorado State 
University, Fort Collins, CO; GenBank accession no. AF327434) and was cloned into 
pXJ40 vector with the addition of HA-tag (previously obtained from Dr. Ed Manser, 
Institute of Molecular and Cell Biology, Singapore). The full-length cDNA was 
generated through PCR with appropriate primers containing either a BamHI or XhoI 
restriction site for cloning into the pXJ40 expression vectors. The residues Phe318, 
Leu321, Phe322, Leu323, and Tyr394 of full-length human KGA were mutated to Ala, 
respectively, as a single-point mutant. Similarly, triple (Leu321- Phe322-Leu323) and 
47 
 
tetra (Leu321-Phe322-Leu323-Tyr394) mutant constructs were mutated to multiple 
alanines (Table 3). We used a polymerase site-directed mutagenesis kit (Kapa 
Biosystems) to create all mutants. The wild-type, constitutive active, or dominant 
negative mutants of the human Raf-1, mouse Mek2 cDNAs were gifts from Dr. Graeme 
Guy, Institute of Molecular and Cell Biology (IMCB), Singapore and their inserts were 
subcloned into Flag or HA-tagged pXJ40 vectors and propagated in E. coli strains DH5α. 
The plasmids were purified, transfected, and Mek2 was validated to activate downstream 
Erk/MAPK as previously described (Pan et al., 2010). Plasmids for protein phosphatase 
PP2A were a gift from Sheng-cai Lin (Xiamen University, Xiamen, China). 
 
Table 3: Deoxyoligonucleotides used to generate mutants of full length KGA 
 
F318A        5'-GCCGAGTGGACTAAGAGCCAACAAACTATTTTTGAAT-3’ 
           5'-ATTCAAAAATAGTTTGTTGGCTCTTAGTCCACTCGGC-3’ 
 
L321A        5'-GTGGACTAAGATTCAACAAAGCATTTTTGAATGAAGATGA-3’ 
        5'-TCATCTTCATTCAAAAATGCTTTGTTGAATCTTAGTCCAC-3’ 
 
F322A           5'-GTGGACTAAGATTCAACAAACTAGCTTTGAATGAAGATGATAAACC-3’ 
          5'-GGTTTATCATCTTCATTCAAAGCTAGTTTGTTGAATCTTAGTCCAC-3’ 
 
L323A       5'-GACTAAGATTCAACAAACTATTTGCGAATGAAGATGATAAACCACA-3’ 
        5'-TGTGGTTTATCATCTTCATTCGCAAATAGTTTGTTGAATCTTAGTC-3’ 
 
Y394A       5'- GAAATTTTGCAATAGGATATGCCTTAAAAGAAAAGAAGTGTTTTC-3’ 
       5'- GAAAACACTTCTTTTCTTTTAAGGCATATCCTATTGCAAAATTTC-3’ 
 
L321A-L323A          5'-GTGGACTAAGATTCAACAAAGCAGCTGCGAATGAAGATGATAAACC-3’ 




Table 4: Deoxyoligonucleotides used to generate mutants of recombinant cKGA 
 
F318Y  5'- CCGTCGGGGCTGCGCTATAATAAACTGTTTCTGAAC -3' 
  5'- GTTCAGAAACAGTTTATTATAGCGCAGCCCCGACGG -3' 
 
F322S  5'- CGCTTTAATAAACTGTCTCTGAACGAAGATGACAAACCG -3' 
  5'- CGGTTTGTCATCTTCGTTCAGAGACAGTTTATTAAAGCG -3' 
 
F318Y/F322S 5'- TCGGGGCTGCGCTATAATAAACTGTCTCTGAACGAAGAT -3' 
  5'- ATCTTCGTTCAGAGACAGTTTATTATAGCGCAGCCCCGA -3' 
 
F394I   5'- CGCAACTTCGCAATTGGGTATATTCTGAAAGAAAAAAAATGCT-3' 
  5'- AGCATTTTTTTTCTTTCAGAATATACCCAATTGCGAAGTTGCG -3' 
 
2.2.9 Cell Proliferation Assays 
293T cells transfected with vector, KGA, or the KGA mutant plasmids were trypsinized 
and replated into 96-well plates, followed by treatment with BPTES for 48 h, and 
amounts of cell proliferations were determined using an MTT proliferation assay kit 
(Promega) as described by the manufacturer. The assay was repeated with at least three 
independent experiments, each with multiple replicates. Statistical significance was 
analyzed using ANOVA and the Student-Newman-Kuels multiple range test 
(StatsDirect). Data are means ± SD (P < 0.05) and expressed as fold increase over control 
cells. 
2.2.10 Coimmunoprecipitation and Western Blot Analyses 
Transfected 293T cells were lysed with Hepes buffer and immunoprecipitated with anti-
Flag M2 affinity gel (Sigma) as previously described (Low et al., 2000). Samples were 
separated in SDS/PAGE gels, followed by Western blot analyses. Blots were probed with 
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polyclonal anti-Flag (Sigma), polyclonal anti-HA (Zymed), anti-KGA (Santa Cruz), anti-
myc (Santa Cruz), anti-Raf (Santa Cruz), anti-Pan-Erk (Cell Signaling Technology), and 
anti-phospho-ERK (Sigma). The luminescence signals were generated by incubation with 
Pierce Pico ECL (Thermo Scientific) as described by the manufacturer. 
 
Cell biology related studies are performed in collaborations with Prof Low Boon Chuan, 
Mechnobiology Institute of Singapore (MBI), NUS. 
 
2.2.11 PDB Accession Codes 
The coordinates of the apo cKGA and its complexes with L-glutamine, L-glutamate, 
BPTES, L-glutamate- BPTES, and inhibitors 2, 3, and 4 have been deposited under 





2.3.1 Purification of Recombinant cKGA 
The human KGA consists of 669 amino acids. We refer to Ile221-Leu533 as the catalytic 
domain of KGA (cKGA) (Figure 11). The plasmid was expressed in Escherichia coli 
BL2 (DE3) RIL-Codon plus cells and the cell pellets were lysed by sonication and 
followed by French press. The protein purification was carried out by two steps: affinity 
purification and followed by gel filtration chromatography. The His6-tagged-cKGA was 
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first purified through affinity purification with the Ni-NTA agarose column. The bound 
protein was eluted in buffer containing 200 mM and 500 mM imidazole, respectively 
(Figure 18).  
      
Figure 8: SDS-PAGE showing the expression and affinity purification profile of His-
tagged cKGA. Samples from different stages of Ni affinity purification were collected, 
verified by coomassie blue stained SDS-PAGE (12.5% gel). Lane 1 – soluble fraction, 
Lane 2 – insoluble fraction, Lane 3 – Flow through,  Lane4– wash 1, Lane5– wash 2, 
Lane6–low molecular weight ladder, Lane7–elution1,  Lane8– elution2, Lane9 –protein 




The eluted protein was further purified through gel filtration chromatography using FPLC 
Hiload 16/200 Superdex200 gel filtration column. A single peak corresponding to the 
molecular weight of cKGA (approximately 36 kDa) was obtained (Figure 19). The eluted 










Figure 9: Gel filtration profile of cKGA in a 120 ml column volume 16/60 Superdex-200 
column. The cKGA protein was purified to homogeneity, as cKGA was eluted as a single 
peak in the gel filtration. Gel filtration fractions from the peak were analyzed through 
12.5% SDS-PAGE analysis. The X-axis indicates the elution volume in mL; Y-axis 
indicates the UV absorbance (at 280 nm) measured in mAU (arbitrary units). 
 
 
Dynamic Light Scattering (DLS) experiment was performed during concentrating the 
protein and prior to the crystallization screenings, to analyze the homogeneity of the 
protein. DLS experiment indicated a dispersity index of 0.11 at 20 mg/ml of protein, and 






Figure 10: Dynamic Light Scattering (DLS) results for purified cKGA. The 
Polydispersity index, and SOS error are indicated in red and blue boxes respectively. 
 
2.3.2 Crystallization  
The initial crystals obtained from the screen were too small to diffract. However, better 
diffraction-quality crystals were obtained through the grid screen optimization process 
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using the crystallization condition of 0.1 M Bis-Tris Propane pH 7.0 and 1.8-2.1 M LiSO4 
(Figure 21).  
            
                           (A)                                                                (B) 
            
                          (C)                                                                (D) 
 
Figure 11: A representative crystals of cKGA. Crystals were obtained from the hanging 
drop vapour diffusion method: (A) apo cKGA crystal (Small), (B) apo cKGA crystal 
(Large), (C) cKGA -L-glutamine complx, (D) cKGA -BPTES  complex.  
 
2.3.3 Data collection, Structure Determination and Refinement 
The crystals were cryo-protected with 15% glycerol and the diffraction data were 
collected at synchrotron beamlines (Figure 22). The apo cKGA and all other complexes 
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crystallized in I4122 space group. The structures of the apo-cKGA, and other complex 
structures were determined by molecular replacement method using the program Molrep 
(Vagin and Teplyakov, 2010) (Table 5).  
 
 
Figure 12: A representative diffraction pattern of apo cKGA crystal. The data collected 
from ADSC Q315 (Area Detector System Corporation) diffractometer system at 13-







Table 5: Crystallographic data and refinement statistics 
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2.3.4 Structures of cKGA and Its Complexes with L-Glutamine and L-Glutamate 
The human KGA consists of 669 amino acids. We refer to Ile221-Leu533 as the catalytic 
domain of KGA (cKGA) (Figure 23A). The crystal structures of the apo cKGA and in 




      
Figure 13: Schematic view and structure of the cKGA-L-glutamine complex. (A) Human 
KGA domains and signature motifs (refer to introduction 1.5.2 for details). (B) Structure 
of the of cKGA and bound substrate (L-glutamine) is shown as a cyan stick. The N- and 
C- termini and the secondary structures such as α-helices and β-sheets are labeled. This 





The structure of cKGA has two domains with the active site located at the interface. 
Domain I comprises (Ile221-Pro281 and Cys424 -Leu533) of a five-stranded anti-parallel 
β-sheet (β2↓β1↑β5↓β4↑β3↓) surrounded by six α-helices and several loops. The domain 
II (Phe282-Thr423) mainly consists of seven α-helices (Figure 25A). 
 
                              
 
Figure 14: Interactions of cKGA with L-Glutamine. Final 2Fo- Fc electron density map 
in the active-site region of cKGA, map contoured at a level of 1 σ. L-Glutamine is shown 
as a cyan stick that makes hydrogen bond interactions with active site residues (orange). 
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L-Glutamine/L-glutamate is bound in the active site cleft (Figure 25B). Overall the active 
site is highly basic, and the bound ligand makes several hydrogen-bonding contacts to 
Gln285, Ser286, Asn335, Glu381, Asn388, Tyr414, Tyr466, and Val484, and these 
residues are highly conserved among KGA homologs (Figure 26).  
 
 
                          
Figure 15: Structure of cKGA and its complex with L-Glutamate. (A) Cartoon 
representation of the apo cKGA structure. Domain I (amino acids 221–281 and 424–533) 
is shown in orange; domain II (amino acids 282–423) in green. The active site cleft is 
located between the interfaces of the domains. (B) Final 2Fo- Fc electron density map in 
the active-site region of cKGA, map contoured at a level of 1 σ. L-Glutamate is shown as 






Notably, the putative serine-lysine catalytic dyad (286-SCVK-289), corresponding to the 
SXXK motif of class D β-lactamase (Brown et al., 2008), is located in close proximity to 
the bound ligand. In the apo structure, two water molecules were located in the active 
site, one of them being displaced by glutamine in the substrate complex. The substrate 
side chain is within hydrogen-bonding distance (2.9 Å) to the active site Ser286. Other 
key residues involved in catalysis, such as Lys289, Tyr414, and Tyr466, are in the 
vicinity of the active site. Lys289 is within hydrogen-bonding distance to Ser286 (3.1 Å) 
and acts as a general base for the nucleophilic attack by accepting the proton from 
Ser286. Tyr466, which is close to Ser286 and in hydrogen bonding contact (3.2 Å) with 
glutamine, is involved in proton transfer during catalysis. Moreover, the carbonyl oxygen 
of the glutamine is hydrogen-bonded with the main chain amino groups of Ser286 and 
Val484, forming the oxyanion hole. Thus, we propose that in addition to the putative 
catalytic dyad (Ser286 XX Lys289), Tyr466 could play an important role in the catalysis 















Figure 16: Sequence alignment of cKGA homologs. The amino acids are in one-letter 
codes, and the conserved residues are in red. Strictly conserved residues are highlighted 
in red (identity <36%). Numbering is shown for the KGA sequence. The key conserved 
catalytic residues of cKGA are shown with asterisks. This figure was prepared using the 
program Espript2.2 (Gouet et al., 1999). The compared cKAG homologs are E. coli YbaS 
(PDB code IU60), Geobacillus kaustophilus (PDB code 2PBY), Bacillus subtilis (PDB 


















Figure 17:  Proposed catalytic mechanism of KGA. The reaction mechanism proceeds 
with the following steps. (i) Formation of tetrahedral intermediate by nucleophilic attack 
of Ser286 on glutamine, which is assisted by Lys289. (ii) Breakdown of tetrahedral 
intermediate to form ammonia and the enzyme intermediate. (iii) Nucleophilic attack of 
water on the enzyme intermediate aided by Lys289 and Try466. (iv) Formation of 







2.3.5 Allosteric Binding Pocket for BPTES 
The crystal structure of cKGA: BPTES complex shows that BPTES occupies a 
previously unsuspected allosteric pocket, in the solvent-exposed region at the dimer 
interface of cKGA, located ≈18 Å away from the active site serine (Ser286). The 
chemical structure of BPTES has an internal symmetry, with two exactly equivalent parts 
including a thiadiazole, amide, and a phenyl group and it equally interacts with each 





Figure 18: Structure of cKGA: BPTES complex. The cKGA homodimer figure is shown 
in ribbon representation. The monomer A and monomer B are shown in purple and 





Figure 19:  Binding pocket for BPTES. A surface representation of the inhibitor binding 
pocket of BPTES; one molecule of BPTES wedged at the interface of two cKGA 
monomers. BPTES is shown as a stick in the transparent view of the surface of cKGA. 
 
The thiadiazole group and the aliphatic linker are well buried in a hydrophobic cluster 
that consists of Leu321, Phe322, Leu323, and Tyr394 from both monomers, which forms 
the allosteric pocket (Figure 30A and 30B). The side chain of Phe322 is found at the 
bottom of the allosteric pocket. The phenylacetamido moiety of BPTES is partially 
exposed on the loop (Asn324-Glu325), where it interacts with Phe318, Asn324, and the 
aliphatic part of the Glu325 side chain. The side chain of Tyr394, backbone amide of the 
Phe322 and Leu323, makes hydrogen-bonding contacts to inhibitors. Moreover, the 
residues Leu321 and Phe322 flipped out ≈180° to enhance the hydrophobic interactions 
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with the inhibitors (Figure 31). Thus, the conformational changes are required to form the 
allosteric pocket.       
                                             
 
 
Figure 20: A close-up view of the interactions of BPTES in the cKGA allosteric inhibitor 
binding pocket. (A) The residues that interact with BPTES from each monomer are 
labeled and shown in different colors consistent with Figure 28. (B) Electron density map 










Figure 21: A schematic view of cKGA monomer interactions with BPTES. For clarity, 
only half of the BPTES inhibitor that interacts with a monomeric cKGA and the 







2.3.6 Inhibitor Optimization of KGA  
The crystal structure of catalytic domain of KGA (cKGA) in complex with BPTES 
(Figure 28) shows that one molecule of BPTES is wedged between two cKGA 
monomers, forming equivalent interactions with each of them. Each of the terminal 
phenylacetamino groups forms fewer interactions with cKGA than the rest of the 
inhibitor. These observations led us to further optimize its inhibitory properties, and 
initially three inhibitors were synthesized (inhibitors 2, 3, and 4) (Figure 32A). Inhibitors 
2, 3, and 4 inhibited cKGA with IC50 values of 8 μM, 11 μM, and 19 μM, respectively 
(Figure 32B). However, BPTES (inhibitor 1) inhibits cKGA with an IC50 of 0.16 μM. 
This clearly indicated the important role of the phenylacetamido group, the length and the 
hydrophobic groups of the linker in cKGA inhibition. To further understand the binding 
mode of these inhibitors, the complex structures of inhibitors 2, 3, and 4 bound to cKGA 
were determined (Table 5 and Figure 33 and 34). Similar to BPTES, compounds 2–4 all 
resides within the hydrophobic cluster of the allosteric pocket and also the side chain of 
Tyr394, backbone amide of the Phe322 and Leu323, makes hydrogen-bonding contacts 
to inhibitors. With these complex crystal structures along with BPTES complex, we 
observed that the inhibitor binding pocket might accommodate larger hydrophobic groups 
and result in synthesizing inhibitor 5 with three methoxy substitutions on both side 
phenyl rings (Figure 32A and Figure 32B). Inhibitor 5 shows an IC50 of 5 μM. This 






        
 
Figure 22: Enzymatic and structural details of BPTES and its derived inhibitors. (A) 
Chemical structure of BPTES (inhibitor 1) and its derivatives. (B) IC50 determination for 
synthesized inhibitors with cKGA. The IC50 values were determined from a plot of 
percentage inhibition against various inhibitors concentration. Each value represents the 
means ± SD of three independent experiments, each with at least three replicates. This 










Figure 23: Details of the interactions of inhibitor 2 in the cKGA inhibitor binding pocket. 
(A) The residues that interact with inhibitor 2 from each monomer are labeled. (B) 
Electron density map (2Fo – Fc map contoured at 1.0σ) for inhibitor 2 (cyan stick) is 











Figure 24: Details of the interactions of inhibitor 3 in the cKGA inhibitor binding pocket. 
(A) The residues that interact with inhibitor 3 from each monomer are labeled. (B) 
Electron density map (2Fo – Fc map contoured at 1.0 σ) for inhibitor 3 (cyan stick) is 
shown in grey mesh.  
 
Although inhibitors 2-5 showed moderate inhibition compared with BPTES, their 
structural details reveal the key determinants for the high potency and selectivity of the 
inhibitors, and guide the design of next-generation inhibitors. Taken together, we propose 
that the binding specificity of BPTES is dictated by the thiadiazole, amide, and the 
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hydrophobic linker regions, whereas the potency is primarily determined by the presence 
of phenyl rings at both ends. Thus, BPTES was subsequently used to further delineate the 
structural, functional, and regulation aspects of KGA. 
 
2.3.7 Allosteric Binding of BPTES Triggers Major Conformational Change in the 
Key Loop Near the Active Site 
The overall structure of these inhibitor complexes superimposes well with apo cKGA. 
However, a major conformational change at the Glu312 to Pro329 loop was observed in 
the BPTES complex (Figure 35). The most conformational changes of the backbone 
atoms that moved away from the active site region are found at the center of the loop 
(Leu316- Lys320). The backbone of the residues Phe318 and Asn319 is moved ≈9 Å and 
≈7 Å, respectively, compared with the apo structure, whereas the side chain of these 
residues moved ≈14 Å and ≈12 Å, respectively. This loop rearrangement in turn brings 
Phe318 closer to the phenyl group of the inhibitor and forms the inhibitor binding pocket, 
whereas in the apo structure the same loop region (Leu316-Lys320) was found to be 
adjacent to the active site and forms a closed conformation of the active site. Specifically, 
in apo structure Phe318 makes hydrophobic interactions with Tyr466, and side chain of 
the Asn319 makes hydrogen- bonding contact with backbone of the Asn335 (≈2.8 Å). 
Notably, the residues Tyr466 and Asn335 are involved in binding to L-glutamine and 
catalysis. These observations suggest that binding of BPTES induces conformational 
changes of the key residues of the loop (Glu312-Pro329) to stabilize an open and inactive 
conformation of the catalytic site. Figure 36A and B show the electrostatic surface 






Figure 25: Conformational changes on cKGA induced by binding of the BPTES. 
Structure superposition of monomeric BPTES complex (magenta) and apo cKGA 
(green), showing conformational changes of key residues on the loop Glu312-Pro329. 
BPTES binding site and active site residues are labeled. The BPTES binding site is 
located ~18 Å away from the active site (Ser286) region. For clarity, only half of the 
BPTES inhibitor that interacts with a monomeric cKGA and the relevant conformational 
changes are shown. 










      
 
Figure 26: Electrostatic surface representation for apo cKGA and cKGA: BPTES 
complex. (A) Electrostatic surface potential of the apo cKGA monomer. Active site 
(Ser286) and BPTES binding site residues were labeled. The active site region is in the 
closed conformation. Blue indicates the positive charge, and red indicates negative 
charge. The position of key residues of the loop Glu312-Pro329 is labeled. (B) 
Electrostatic surface potential of the BPTES: cKGA monomer. Same residues as 
described in A are shown here. The active site is in the open conformation with the 
residues Phe318 and Asn319 are moved away. The position of the key residues is labeled. 
A and B show the difference in the electrostatic surface potential and molecular surface 






Besides, we have determined the cKGA-glutamate-BPTES structure and revealed similar 
conformational changes, suggesting that BPTES can stabilize an inactive glutamate- 
bound form of the enzyme (Figure 37). This result is consistent with previous kinetics 
studies showing that BPTES, which is an uncompetitive inhibitor, can inhibit both the 






Figure 27: Structure of cKGA-glutamate-BPTES complex. The BPTES molecule, shown 
as a cyan stick, is located at the dimer interface and its interacting loops (Glu312- 
Pro329) from each monomer. The glutamate molecules are shown as magenta stick in the 




2.3.8 Binding of BPTES Stabilizes the Inactive Tetramers of cKGA  
To understand the role of oligomerization in KGA function, dimers and tetramers of 
cKGA were generated using the symmetry-related monomers (Figure 38).  
 




Figure 28: A close-up view of the BPTES binding pocket. BPTES binding pocket is 
located on the surface exposed region of the loop Glu312-Pro329 at the dimer interface. 
 
The dimer interface in the cKGA: BPTES complex is formed by residues from the helix 
Asp386-Lys398 of both monomers and involves hydrogen bonding, salt bridges, and 
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hydrophobic interactions (Phe389, Ala390, Tyr393, and Tyr394), besides two sulfate ions 
located in the interface (Figure 38 and Figure 39).     
 
 




Figure 29: Perpendicular view of dimer interface of the cKGA-BPTES homodimer and 
showing the residues involved in the interaction as sticks. The dimerization interface is 
formed by the sulphate ion, hydrogen bonding, salt bridge, and hydrophobic interactions 
between residues from each monomer. The sulphate ion and the hydrogen bonding 




The dimers are further stabilized by binding of BPTES, where it binds to loop residues 
(Glu312-Pro329) and Tyr394 from both monomers. Similarly, residues from Lys311-
Asn319 loop and Arg454, His461, Gln471, and Asn529-Leu533 are involved in the 
interface with neighboring monomers to form the tetramer in the BPTES complex. 
Furthermore, the tetrameric structure of the apo and BPTES: cKGA complex reveals a 
significant difference in the interface area of each monomer. These interactions are 
relatively weak in the apo tetramer compared with the BPTES complex. The apo tetramer 
has a total of 16 intermolecular hydrogen bond contacts (<3.2 Å) with a buried area of 
≈1,700 Å2 of each monomer, whereas in the cKGA: BPTES complex there are 25 
intermolecular hydrogen bond contacts with a buried area of ≈1900 Å2. The interactions 
among the monomers are relatively weaker in the apo tetramer than in the BPTES 
complex Figure 40A and B). We infer that the binding of BPTES promotes the formation 
of a stable but inactive tetramer. 
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Figure 30: Surface representation showing the apo cKGA and cKGA: BPTES tetramer 
(A) Surface representation showing the symmetry-related apo cKGA molecules forms a 
tetramer. Each monomer is colored differently (A, orange; B, purple; C, blue; D, green). 
(B) Surface representation showing the symmetry-related BPTES: cKGA forms tetramer. 
Each monomer is shown in same color as described in A. The BPTES: cKGA forms tight 




2.3.9 BPTES Induces Allosteric Conformational Changes That Destabilize Catalytic 
Function of KGA 
Subsequently we examined how BPTES binding could inhibit KGA activity by 
comparing the structures of the cKGA: BPTES inhibitor complex with the apo cKGA 
structure. Because the loop Glu312-Pro329 is located near the active site, we hypothesize 
that BPTES binding induces conformational changes of the key residues of the loop 
(Glu312-Pro329) to stabilize an open and inactive conformation of the catalytic site. To 
test this hypothesis, wild-type KGA and structure-guided KGA mutants Phe318Ala, 
Leu321Ala, Phe322Ala, and Leu323Ala, as well as a Tyr394Ala variant from the 
dimerization helix, were each expressed in human embryonic kidney epithelial cells 293T 
at equal levels, and homeostasis levels of glutamate inside the cells were determined. 
Figure 41 shows that HEK 293T cells overexpressing KGA produced a higher level of 
glutamate compared with the vector control cells. Most significantly, all of these mutants, 














Figure 31: Mutations at allosteric loop and BPTES binding pocket abrogate KGA 
activity. HEK 293T cells were transfected with vector control or plasmids expressing 
wild-type, single, or multiple point mutants of HA-tagged KGA for 24 h before cell 
lysates were prepared for glutaminase assays. For clarity, the dotted line was included to 
indicate the basal level. Equal expression levels of the wild-type and mutants KGA were 




Next, we examined whether these residues are specifically involved in stabilizing the 
BPTES–KGA interactions. Unlike all of the previous mutants that have Ala substitutions 
to knock out their direct contribution to the actual enzymatic activities, a set of 
recombinant cKGA mutants (Phe318Tyr, Phe322Ser, Phe318Tyr/Phe322Ser, and 
Tyr394Ile) were instead generated to test their BPTES sensitivity. In particular, 
Phe318Tyr/Phe322Ser double mutant was used to mimic the corresponding residues in 
the liver form of glutaminase, LGA. Results show that all these mutants still retain the 
80 
 
same KGA activity as the wild-type control (Figure 42). However, the three mutants 
Phe322Ser or Phe318Tyr/ Phe322Ser and Tyr394Ile showed significantly reduced 
sensitivity to BPTES (1,140-, 970-, and 910-fold, respectively) (Figure 43). In contrast, 
Phe318Tyr, which retains the aromatic ring and is still active, remains highly sensitive to 
BPTES. In summary, consistent with our structural analysis, all of the key residues in the 
loop Glu312 to Pro329 and Tyr394 are essential for conferring KGA activity, and at least 
Phe322 and Tyr394 are involved in stabilizing the BPTES–KGA interaction. Any 
conformational change upon BPTES binding would severely affect the stability of the 





Figure 32: Glutaminase assay of cKGA mutants. Wild-type, F318Y, F322S, 
F318Y/F322S (a double mutant), and Y394I mutant of the cKGA were expressed, 





   
Figure 33: Mutational analyses of cKGA residues in the BPTES binding pocket. BPTES 
sensitivity for the wild-type and cKGA mutants indicated were measured and their IC50 
values calculated. Each value represents the mean ± SD of three independent experiments 
performed in duplicate. 
 
2.3.10 Raf-Mek-Erk Signaling Module Regulates KGA Activity 
To demonstrate that treatment of cells with BPTES indeed inhibits KGA activity and cell 
proliferation, both 293T and MCF7 cells were treated with various concentrations of 
BPTES. Figure 44A and B show that BPTES abolished any increase in the glutamate 
levels in 293T and MCF7 cells overexpressing KGA, down to the basal level in a dose 
dependent manner, with more than 75% of the activity inhibited with 10 μM and 
completely inhibited with 50 μM of BPTES (Figure 44C). Consequently, treatment with 
BPTES in these cells also reduced cell proliferation in a dose-dependent manner (Figure 






Figure 34: BPTES inhibits both KGA activity and cell proliferation in a dose-dependent 
manner. HEK 293T (A) and MCF7 (B) cells expressing a vector control or HA-tagged 
KGA were treated with DMSO or 50 μM of BPTES for 48 h. Cells were lysed and 
assayed for glutaminase activity. Equal expression levels of KGA were verified by 
Western blots. All values are means ± SD of three independent experiments, each with at 
least three replicates. Data sharing different letters are statistically significant at P values 
as indicated, as tested by ANOVA. (C) BPTES inhibits KGA activity in HEK 293T cells 
in a dose-dependent manner. HEK 293T cells expressing KGA were treated with the 
range of BPTES concentration as indicated. Cells were lysed and assayed for glutaminase 
activity. Equal expression levels of KGA were verified with Western blot analyses. (D) 
BPTES inhibits cell proliferation in HEK 293T cells in a dose-dependent manner. HEK 
293T cells were seeded into 96-wells and treated with various indicated concentrations of 
BPTES for 48 h, and cell proliferation assays were measured. All values are means ± SD 
of three independent experiments, each with at least three replicates. Data sharing 




Next, as cells respond to various physiological stimuli to regulate their metabolism, with 
many of the metabolic enzymes being the primary targets of modulation (Tennant et al., 
2010), we examined whether KGA activity can be regulated by physiological stimuli, in 
particular EGF (epidermal growth factor), which is important for cell growth and 
proliferation. Cells overexpressing KGA were made quiescent and then stimulated with 
EGF for various time points. Figure 45 shows that the basal KGA activity remained 
unchanged 30 min after EGF stimulation, but the activity was substantially enhanced 
after 1 h and then gradually returned to the basal level after 4 h. Because EGF activates 
the Raf-Mek-Erk signaling module (Roberts and Der, 2007), treatment of cells with Mek-
specific inhibitor U0126 could block the enhanced KGA activity with parallel inhibition 
of Erk phosphorylation (Figure 45). Interestingly, such Mek-induced KGA activity is 
specific to EGF and lysophosphatidic acid (LPA) but not with other growth factors, such 


















Figure 35: EGFR-Raf-Mek-Erk signaling stimulates KGA activity (i). (A) 293T cells 
expressing HA-tagged KGA were starved for 24h and then stimulated with EGF (100 
ng/mL) for the times indicated. Cells were lysed and assayed for their glutaminase 
activities. (B) The expression levels of KGA and the Erk activation profile (as indicated 
by levels of phosphorylated Erk) were verified by Western blot analyses. All values are 
mean ± SD of three independent experiments, each with multiple replicates. Data sharing 










Figure 36: Regulation of KGA by different growth factors and stimuli. 293T cells 
expressing HA-tagged KGA were starved and stimulated with various mitogens including 
EGF (100 ng/mL), LPA (20 μM), PDGF (50 ng/mL), TGF-β (1 ng/mL), and bFGF (10 
ng/mL) as indicated for 3 h. The cells were lysed and assayed for glutaminase activity. 
Equal expression of KGA and signaling activation (as indicated by levels of 
phosphorylated Erk) were verified with Western blot. Values are means ± SD of three 
independent experiments, each with multiple replicates. Data sharing different letters are 
statistically significant at P values as indicated, as tested by ANOVA.  
 
 
We next investigated whether Raf-Mek-Erk activated by EGF could indeed directly 
regulate the KGA activity. Cells were transfected with KGA with wild-type, the 




Mek2 and the levels of glutamate determined. Strikingly, KGA activity was completely 
inhibited by both the dominant negative mutants of Raf-1 (K375M) and Mek2 (K101A), 
whereas both wild-type and constitutive active mutants of Raf-1 (Raf-1-Y340D) and 
Mek2 (Mek2-S222, 226D) did not lead to any further increase in the glutamate 
production (Figure 47A). Moreover, expression of these mutants did not affect the 
expression levels of either ectopically expressed or the endogenous level of KGA (Figure 
47B and 47C), indicating that any changes in the KGA activity was not due to their 
protein stability but was due to some posttranslational modifications of KGA. To 
examine whether such regulation is directly associated with the Raf-Mek-Erk complex, 
overexpressd KGA was immunoprecipitated from the cells, and the presence of Raf-1, 
Mek2, or Erk1/2 (endogenous or overexpressed) was examined. The results show that 
KGA could interact equally well with the wild-type or mutant forms of Raf-1 and Mek2 
(Figure 47C). Importantly, endogenous Raf-1 or Erk1/2, including the phosphorylated 
Erk1/2 (Figure 47C and 47D), could be detected in the KGA complex. Taken together, 
these results indicate that the activity of KGA is directly regulated by Raf-Mek-Erk 
downstream of EGF receptor.  
 











                        
          
          
                                                                       
Figure 37: EGFR-Raf-Mek-Erk signaling stimulates KGA activity (ii). (A) Cells expressing Flag-tagged KGA with or without the HA-tagged wild-type, 
dominant negative mutants (Raf-1-K375M; Mek2-K101A) or constitutive active mutants (Raf-1-Y340D; Mek2-S222, 226D) were lysed and assayed for 
glutaminase activity. (B) Ectopic expression of the Mek2 mutants does not affect the endogenous levels of KGA. 293T cells expressing wild-type and mutants of 
Mek2 (Mek2-K101A; Mek2-S222, 226D) were lysed, and the endogenous levels of KGA of these samples were analyzed by Western blot. (C) Same batch of 
cell lysates prepared for the glutaminase assay in A were subjected to immunoprecipitation (IP) with anti-Flag M2 beads. Bound proteins and their expression in 
whole-cell lysates (WCL) were analyzed with Western blot. (D) Cells expressing Flag-tagged KGA were lysed for immunoprecipitation using anti-Flag M2 
beads and analyzed for the presence of endogenous Raf-1 or Erk1/2 by Western blot analyses. Arrow denotes band for Raf-1. Values are means ± SD of three 





To further show that Mek2-enhanced KGA activity requires both the kinase activity of 
Mek2 and the core residues for KGA catalysis, wild-type or triple mutant 
(Leu321Ala/Phe322Ala/ Leu323Ala) of KGA was coexpressed with dominant negative 
Mek2-KA or the constitutive active Mek2-SD and their KGA activities measured. The 
result shows that the presence of Mek2- KA blocks KGA activity, whereas the triple 
mutant still remains inert even in the presence of the constitutively active Mek2 (Figure 
48A), and despite Mek2 binding to the KGA triple mutant (Figure 48B). Consequently, 


















   
 
 
Figure 38: EGFR-Raf-Mek-Erk signaling stimulates KGA activity (iii). (A) 293T cells 
were transfected with vector control or plasmids expressing wild-type KGA or the KGA 
triple mutant (L321A/F322A/L323A), in the absence or presence of Mek2-K101A or 
Mek2-S222,226D for 24 h before lysates were prepared for glutaminase assays. 
Expression levels of these proteins were verified by Western blot analyses. (B) 293T cells 
transfected with wild-type and triple mutant of HA-tagged KGA in the presence of Flag-
tagged Mek2-SD were lysed for immunoprecipitation with anti-Flag M2 beads and 
analyzed for their interaction with Western blot analyses. (C) 293T cells were transfected 
with plasmids expressing wild-type KGA, or the triple-mutant for 24 h, and reseeded 
with equal number into 96-well plates for another 48 h before being assayed for cell 
proliferation. All values for glutaminase and proliferation assays are means ± SD of three 
independent experiments, each with multiple replicates. Data sharing different letters are 






We have demonstrated that the KGA activity is dependent on the regulation of Raf-Mek2 
signaling and core residues for KGA catalysis. To determine its physiological relevance, 
we tested whether blocking Raf-Mek2 signaling by the dominant negative mutant of 
Mek2, and inhibiting KGA by BPTES, could lead to any synergistic effect on cell 
proliferation. Cells were made to overexpress KGA or/ and Mek2-K101A, and then 
treated with 20 μM of BPTES for the next 24 h. Figure 49 shows that transient expression 
of Mek2-K101A alone did not affect cell proliferation. However, it reduced the level of 
cell proliferation by 10% when cells were treated with a subthreshold dose of BPTES 
which by itself did not lead to any loss of cell proliferation over this period of treatment. 
Interestingly, when cells expressing both KGA and Mek2-K101A were treated with 
subthreshold levels of BPTES, there was a further reduction in cell proliferation by 30% 
(p < 0.02). 
 
Figure 39: Dominant negative form of Mek2 potentiates BPTES inhibition on cell 
proliferation. Cell expressing KGA and/or the Mek2-K101A for 24 h were re-seeded with 
equal numbers into 96-well plates, followed by treatment with suboptimal concentration 
of BPTES (20 μM) for a further 24 h before being assayed for cell proliferation. Values 
are means ± SD of three independent experiments, each with multiple replicates. Data 





Lastly, to determine whether regulation of KGA by Raf- Mek-Erk depends on its 
phosphorylation status, cells were transfected with KGA with or without the protein 
phosphatase PP2A and assayed for the KGA activity. PP2A is a ubiquitous and conserved 
serine/threonine phosphatase with broad substrate specificity. The results indicate that 
KGA activity was reduced down to the basal level in the presence of PP2A (Figure 50 
A). Coimmunoprecipitation study also revealed that KGA interacts with PP2A (Figure 
50B), suggesting a negative feedback regulation by this protein phosphatase. 
Furthermore, treatment of immunoprecipitated and purified KGA with calf-intestine 
alkaline phosphatase (CIAP) almost completely abolished the KGA activity in vitro 
(Figure 50C). Taken together, these results indicate that KGA activity is regulated by 
Raf-Mek2 signaling, and KGA activation by EGF could be part of the EGF-stimulated 
Raf-Mek-Erk signaling program in controlling cell growth and proliferation (Figure 51). 
 













Figure 40: KGA activity is regulated by phosphorylation. (A) Lysates were prepared 
from cells expressing Flag-tagged KGA in the presence or absence of myc-tagged 
catalytic subunit of the protein phosphatase PP2A and assayed for the glutaminase 
activity. Values are means ± SD of three independent experiments. Data sharing different 
letters are statistically significant at P < 0.02, as tested by ANOVA. (B) Separate aliquots 
from the same batch of cell lysates prepared for the glutaminase assay in A were 
subjected to immunoprecipitation (IP). Bound myc-PP2A and their expression levels in 
whole-cell lysates (WCL) were analyzed by Western blots. (C) Cell lysates containing 
Flag-tagged KGA were immunoprecipitated with anti-flag M2 beads, washed and then 
treated with or without the calf intestine alkaline phosphatase CIAP at 37 °C for 3 h 
before assayed for glutaminase activity. Values are means +/− SD of 3 independent 
experiments. Data sharing different letters are statistically significant at P < 0.005, as 







Figure 41: Schematic model depicting the synergistic cross-talk between KGA-mediated 
glutaminolysis and EGF-activated Raf-Mek-Erk signaling. Exogenous glutamine can be 
transported across the membrane and converted to glutamate by glutaminase (KGA), thus 
feeding the metabolite to the ATP-producing tricarboxylic acid (TCA) cycle. This 
process can be stimulated by EGF receptor mediated Raf-Mek-Erk signaling via their 
phosphorylation-dependent pathway, as evidenced by the inhibition of KGA activity by 
the kinase-dead and dominant negative mutants of Raf-1 (Raf-1-K375M) and Mek2 
(Mek2- K101A), protein phosphatase PP2A, and Mek-specific inhibitor U0126. 
Consequently, inhibiting KGA with BPTES and blocking Raf-Mek pathway with Mek2-







Small-molecule inhibitors that target glutaminase activity in cancer cells are under 
development. Earlier efforts targeting glutaminase using glutamine analogs have been 
unsuccessful owing to their toxicities (DeBerardinis et al., 2008; Ovejera et al., 1979). 
BPTES has attracted much attention as a selective, non-toxic inhibitor of KGA (Robinson 
et al., 2007), and preclinical testing of BPTES toward human cancers has just begun 
(Garber, 2010). BPTES selectively suppresses the growth of glioma cells (Seltzer et al., 
2010) and inhibits the growth of lymphoma tumor growth in animal model studies (Le et 
al., 2012). Wang et al. (Wang et al., 2010) reported a small molecule that targets 
glutaminase activity and oncogenic transformation. Despite extensive studies, nothing is 
known about the structural and molecular basis for KGA inhibitory mechanisms and how 
their function is regulated during normal and cancer cell metabolism. Such limited 
information impedes our effort in producing better generations of inhibitors for better 
treatment regimens. 
 
Comparison of the complex structures with apo cKGA structure, which has well-defined 
electron density for the key loop, we provide the atomic view of an allosteric binding 
pocket for BPTES and elucidate the inhibitory mechanism of KGA by BPTES. The key 
residues of the loop (Glu312-Pro329) undergo major conformational changes upon 
binding of BPTES. In addition, structure-based mutagenesis studies suggest that this loop 
is essential for stabilizing the active site. Therefore, by binding in an allosteric pocket, 
BPTES inhibits the enzymatic activity of KGA through (i) triggering a major 
conformational change on the key residues that would normally be involved in stabilizing 
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the active sites and regulating its enzymatic activity; and (ii) forming a stable inactive 
tetrameric KGA form. Our findings are further supported by two very recent reports on 
KGA isoform (GAC) (Cassago et al., 2012; DeLaBarre et al., 2011) although these 
studies lack full details owing to limitation of their electron density maps. BPTES is 
specific to KGA but not to LGA (Robinson et al., 2007). Sequence comparison of KGA 
with LGA (Figure 52A) reveals two unique residues on KGA, Phe318 and Phe322, which 
upon mutation to LGA counterparts, become resistant to BPTES. Thus, our study 
provides the molecular basis of BPTES specificity.  
 
It was recently reported that KGA is up-regulated by Myc and Rho and is subjected to 
ubiquitination (Colombo et al., 2010; Gao et al., 2009; Wang et al., 2010). However, little 
is known regarding how the glutaminolytic pathway is functionally linked to growth-
promoting signaling pathway(s). Many metabolic enzymes are thought to serve as 
housekeeping enzymes that control fluxes of metabolites to sustain rather than to 
primarily regulate cell growth. Here we show that a high level of KGA activity can lead 
to the increased cell proliferation that is inhibited by BPTES. Most significantly, we 
show that KGA activity is activated by EGF via the Raf-Mek-Erk signaling module 
because inhibition of both kinases by their dominant negative mutants or treatment with a 
specific Mek inhibitor completely abrogates the KGA activity. Consistent with the 
regulation being phosphorylation-dependent, co-expressing KGA with protein 
phosphatase PP2A or treatment of purified KGA with alkaline phosphatase all block the 
elevated KGA activity. When key residues on the loop that stabilizes the catalytic core of 
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KGA are mutated, such stimulation is lost. These results indicate that Raf-Mek-Erk 





Figure 42: Sequence and structure-based analysis of KGA. (A) Sequence alignment 
between KGA with LGA around the BPTES binding pocket. The residues that form the 
binding pocket of BPTES are marked with asterisks. The sequence identity between full-
length human KGA and full-length LGA is 63%, and their glutaminase domain alone is 
81%. Numbering is shown for the KGA sequence. The figure was prepared using 
Espript2.2 (Gouet et al., 1999). (B) Superposition of the domain II of the cKGA with 
death domain containing protein (PDB code: 2OF5). Cα trace showing the superposition 
of domain II of the cKGA (magenta) and death domain of the TNF superfamily protein 
(yellow). These two protein domains superimpose with an rmsd of 2.9 Å for 91 Cα 





We show that the combined inhibitory effect of Mek2 and BPTES on KGA and cell 
proliferation could offer an exciting regime for multidrug therapy in cancers. 
Understanding how KGA itself is activated by the Raf-Mek signaling will also provide an 
alternative approach to further examine whether deregulation of KGA and its 
hyperactivation can be linked to this pathway. This could be the basis for abnormal cell 
growth in cancers and possibly other metabolic and neuronal disorders involving 
glutamate or ammonia as a main metabolite, such as hyperinsulinism/ hyperammonemia/ 
hepatic encephalopathy and neurotransmission (Kelly and Stanley, 2001; Romero-Gómez 
et al., 2010). In this regard, we show that KGA forms a complex with Raf-1, Mek2, and 
Erk1/2, as well as the protein phosphatase PP2A, which can be anchored on a common 
scaffold protein or present as different subcomplexes. Whether this activation would 
involve KGA directly as a substrate of Raf-1, Mek2, or/and Erk or whether other 
immediate substrate(s) of these kinases exist to act as a co-regulator for KGA remains to 
be further investigated. This is of particular interest because we show that bFGF, despite 
activating Mek/Erk, does not activate the KGA activity. This result highlights tight 
regulation of these three-tier kinases that could be spatially coordinated through different 
scaffolds or by other yet-unknown coregulators. In addition, the domain II of cKGA is 
homologous to several DEATH domain-containing proteins (Figure 52B), which are 





In summary, the current structural, biochemical, molecular, and cell-based studies 
provide detailed insights into allosteric inhibition of human KGA by BPTES, the 
regulation of KGA activity and cell proliferation by EGF receptor-mediated Raf/ 
Mek/Erk signaling module, and phosphorylation-dependent regime in cancer cell 
metabolism. This could pave the way for developing more specific therapeutic inhibitors 
toward KGA and Mek2-linked pathways and may offer a more effective strategy to 





























Structural basis of the active site 
inhibition mechanism of human kidney 










The glutamine analogue, 6-Diazo-5-oxo-L-norlucine (DON), was previously shown to 
inhibit KGA through binding to the active site (Shapiro et al., 1979). DON is an antibiotic 
that was originally isolated from Streptomyces. It is a diazo analogue of L-glutamine and 
known to interfere with a number of nucleotide and protein synthetic pathways where 
glutamine primarily act as a nitrogen substrate (Kisner et al., 1980). However, DON lacks 
selectivity against glutaminase, because it is structurally similar to glutamine that was 
shown to inhibit many glutamine utilizing enzymes such as amidotransferases, and 
glutamine synthetase (Ortlund et al., 2000; Pinkus, 1977). The potential anticancer 
activity of DON has been studied in different animal models; however, it has not 
progressed to clinical trials due to the toxicity concerns (Ahluwalia et al., 1990; Ovejera 
et al., 1979), so it warrants the optimization. In addition to DON, the glutamate analogue 
CK (L-2-amino-4-oxo-5- chloropentanoic acid) was previously reported to act on the 
active site of KGA. DON is shown to be more effective at high concentrations of 
phosphate to inhibit KGA (Shapiro et al., 1979) whereas CK effectively inhibits KGA in 
decreased phosphate concentrations (Shapiro et al., 1978). 
Recent crystal structure of glutaminase from Bacillus subtilis, with the DON bound form 
reveals the key role of a serine residue as a catalytic nucleophile (Brown et al., 2008). We 
recently reported the crystal structure of catalytic domain of kidney type glutaminase 
(cKGA) in complex with L-glutamine and L-glutamate in active site and proposed the 
catalytic mechanism of KGA (Thangavelu et al., 2012). The catalytic dyad of KGA 
consists of Ser286 and Lys289, with the Ser286 acting as a catalytic nucleophile. In 
addition, we and others have reported the allosteric inhibition mechanism of KGA/ and 
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GAC isoforms by BPTES (DeLaBarre et al., 2011; Thangavelu et al., 2012). Moreover, 
we recently have shown that KGA activity can be regulated by Ras\Raf\Mek\Erk 
signaling in response to growth factor stimulation (Thangavelu et al., 2012). 
Subsequently, Cassaga et al. have solved the structure of GAC isoform in complex with 
phosphate, and they proposed the activation mechanism of GAC isoform (Cassago et al., 
2012).  
So far, there has been no crystal structure reported for any of KGA isoforms in complex 
with active site inhibitors. Previous kinetic studies have suggested that DON could act on 
the active site of the glutaminase (Robinson et al., 2007; Shapiro et al., 1979). 
Nevertheless, the structural basis for the active site inhibition mechanism of DON 
towards human KGA remains to be elucidated. As a first step towards improving its 
potency and selectivity with KGA, here we report the crystal structure of cKGA in 
complex with DON, refined to 2.3 Å resolution. The complex structure revealed the DON 
binding pocket of KGA. DON makes covalent bond contact with active site residue 
Ser286 of KGA. Further we performed site-directed mutagenesis to validate the 
importance of key residues involved in interactions with DON. Based on our studies, 








3.2 Materials and Methods 
3.2.1 Expression and Purification of cKGA 
Human cKGA was purified following the procedures described in the chapter II. The 
purified protein (20 mg/mL) was kept in a storage buffer (20 mM Na-Hepes pH 7.5, 200 
mM NaCl, 10% glycerol and 3 mM DTT) and used for crystallization experiments.  DON 
(6-diazo-5-oxo-L-norleucine, NSC 7365), azaserine (O-diazoacetyl-L-serine, NSC 742), 
Glufosinate Ammonium, and L-Methionine Sulfoximine were purchased from Sigma. 
 
2.2.3 Glutaminase Assay  
Glutaminase assay was performed using a two step assay described previously (Kenny et 
al., 2003). Briefly, 10 μL of wild-type cKGA or cKGA alanine mutant was incubated 
separately with 10 μL of first assay mix [20 mM glutamine, 50 mM Tris·acetate (pH 8.6), 
100 mM phosphate, and 0.2 mM EDTA] at 37 °C for 10 min, and the reaction was 
quenched with adding 2 μL of 3 M HCl. Subsequently 200 μL of the second assay mix 
[2.2 U glutamate dehydrogenase, 80 mM Tris·acetate (pH 9.4), 200 mM hydrazine, 0.25 
mM ADP, and 2 mM nicotinamide adenine dinucleotide] was added and incubated for 30 
min at room temperature. The absorbance at 340 nm was recorded using a microplate 
reader (SpectraMax 340; Molecular Devices). Compounds were prepared as a 10-mM 
stock in water. The IC50 values were calculated from the fitted regression equation using 
the-log plot (Graphpad prism). Each value represents the means ± SD of three 





3.2.2 Crystallization and Data Collection 
Crystallization screening was carried out by hanging drop vapor diffusion methods at 
22ºC. Prior to crystallization the complex was made by incubating 20 mg/mL of cKGA 
with 10 mM DON (approximately 1:10 molar ratio) for 30 minutes at 4 °C. The 
crystallization drop consists of 1 µl cKGA: DON complex and 1 µl of the crystallization 
solution from the reservoir well. The cKGA: DON crystals grew after 2 days in the 
presence of 0.1 M Bis-Tris Propane pH 7.27 and 1.83 M LiSO4. For the diffraction 
studies, crystals were cryo-protected with the reservoir solution supplemented with 15% 
glycerol as a cryoprotectant and flash frozen in liquid nitrogen. Diffraction data were 
collected at the synchrotron beam line 13B1 (wavelength 1.000 Å) at National 
Synchrotron Radiation Research Centre (NSRRC, Taiwan). Data sets were processed and 
scaled resolution using HKL2000 (Otwinowski Z and W., 1993). The crystallographic 
data collection statistics are provided in Table 7. 
 
3.2.3 Structure Solution and Refinement 
The structure of cKGA-DON complex was determined by molecular replacement using 
the program MolRep (Vagin and Teplyakov, 2010) using the coordinates of apo cKGA as 
the search model (Protein data bank 3VOY, (Thangavelu et al., 2012). One molecule of 
cKGA: DON complex was observed in the asymmetric unit. The initial R-factor was 39% 
for cKGA: DON complex from the molecular replacement solution. The model was 
examined and built in COOT (Emsley and Cowtan, 2004) and subsequent refinement 
carried out with Phenix-refine (Zwart et al., 2008). Fitting of the inhibitor and 
refinements were carried out in COOT and Phenix programs respectively. Water 
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molecules were included at the final stage of the refinement. The final structure was 
refined up to 2.3 Å resolution with the R-factor and R-free values of 19% and 21% 
respectively.  The overall geometry of final model was analyzed by Ramachandran plot 
with the program PROCHECK (Laskowski RA et al., 1993). Details of the refinement 
statistics are provided in Table 7.  
 
3.2.4 Site-Directed Mutagenesis of cKGA  
We performed site-directed mutagenesis using the kit from Kapa biosystems to create all 
structure-guided mutants of cKGA (Table 6). The cKGA cloned into the PET-28 (b) 
vector was used as a template for mutagenesis. The residues Tyr249, Ser286, Lys289, 
and Tyr466 of cKGA were mutated to Ala, respectively, as a single-point mutant. All 
mutations were verified by DNA sequencing. Plasmids containing the point mutations 
were transformed into the E. coli BL21 (DE3) RIL strain and the mutant cKGA proteins 
were over expressed and purified in the similar manner as the wild-type cKGA.   
 
Table 6: Deoxyoligonucleotides used in this work 
 
Y249A  5'-GGGAAAGTTGCGGATGCTATTCCGCAGCTGGCC-3’ 
  5'-GGCCAGCTGCGGAATAGCATCCGCAACTTTCCC-3’ 
 
S286A  5'-TCTGCCTGCAAGCCTGTGTGAAACCGCTGAAAT-3’ 
  5'-ATTTCAGCGGTTTCACACAGGCTTGCAGGCAGA-3’ 
 
K289A   5'-CTGCAAAGCTGTGTGGCACCGCTGAAATACGCG-3’ 
                5'-CGCGTATTTCAGCGGTGCCACACAGCTTTGCAG-3’ 
 
Y466A  5'-CACTCATGCGGGATGGCTGACTTTTCCGGCCAA-3’ 




3.3 Results and Discussions 
 
3.3.1 Inhibition studies of cKGA by Glutamine and Glutamate analogues 
DON and azaserine are glutamine analogs that are known to inactivate several glutamine-
utilizing enzymes such as glutaminase, amidotransferases and glutamine synthetase 
(Barclay and Phillipps, 1966). Besides glutamine analogs, two other glutamate analogs 
such as glufosinate ammonium and L-methionine sulfoximine were previously shown to 
inhibit the glutamate dependent enzymes (Gill and Eisenberg, 2001; Liaw and Eisenberg, 





Figure 43: Inhibition studies of cKGA with selected glutamine/glutamate analogs. The 
relative inhibition percentage of cKGA by selected glutamine/glutamate analog inhibitors 
at 1 mM concentration (IC50 of DON: approximately 0.991 mM) was compared. The 
assays were performed in triplicates and values are means +/− SD of three independent 





Inhibition assay showed that DON inhibits cKGA with an inhibition value (IC50) of 
approximately 0.991 mM. However, compared to DON, cKGA activity was not 
significantly inhibited by other three inhibitors (Figure 53). Thus, DON was taken 
forward to study KGA’s active site based inhibition mechanism. Towards this objective 
we have determined the complex structure of cKGA and DON.  
 
3.3.2 Crystallization and Data Collection   
Single crystals of cKGA: DON complex were obtained after 2 days in hanging drop 
vapour diffusion method and were grown to full size in 5 days (Figure 54). The crystals 
were cryo-protected with 15% glycerol and the data was collected at synchrotron source.  
 
                                       
 
Figure 44: The cKGA: DON complex crystals were obtained with the reservoir solution 





Table 7: Crystallographic data and refinement statistics for cKGA: DON complex 
 
 
 cKGA: DON complex                                     
Space group I4122 
Cell parameters (Å, º) 
a= 139.27,b= 139.27,c= 
156.50, α= β=γ=90 
Resolution range (Å) 30-2.3 (2.34-2.30) 
Wavelength (Å) 1.000  
Observed hkl  392469 
Unique hkl  34102 
Completeness (%)  99.6 (95.7) 
Overall I/σI  12.7 
a
Rsym  
  0.054 (0.392) 
 
Refinement and quality of the model  
*Resolution range  25.7-2.30  
b
Rwork (%) no. reflections  19.28 (23221) 
c
Rfree (%) no. reflections  21.08 (1722)               
Root mean square deviation  
Bond length (Å)  0.007 
Bond angle (º)  1.02 
Ramachandran plot (%)  
Favored region  88.1 
Allowed regions  11.2 
Generously allowed region  0.7 





Main chain atoms  52.04 
Side chain atoms  57.43 
Overall protein atoms (no. 
atoms)  
54.63 (2412) 
Waters (no. atoms)  54.63 (89) 




 Rsym = |Ii − <I>|/|Ii| where Ii is the intensity of the i
th
 measurement, and <I> is the 
mean intensity for that reflection. 
b 
Rwork = |Fobs − Fcalc|/|Fobs| where Fcalc and Fobs are the calculated and observed 
structure factor amplitudes respectively. 
c
 Rfree is as for Rwork, but only for 5.06% of the total reflections chosen at random and 
omitted from refinement. 
d




As shown in table, a complete data set was collected up to a resolution of 2.3 Å (Table 7). 
The data were scaled with I4122 space group with the Rsymm <0.1, suggesting the good 
quality of the data.  
 
3.3.3 Overall Structure of cKGA: DON complex 
 
                      
 
Figure 45: Ribbon representation of the cKGA: DON complex. The secondary structures 
such as α-helices and β-sheets are shown in cyan and magenta, respectively. The DON is 
located in the active site cleft and is shown as yellow stick. This figure was prepared 
using Pymol (DeLano, 2002).  
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The structure was determined by the molecular replacement method using coordinates 
derived from apo cKGA (PDB code 3voy). The final model has been refined with good 
stereochemical parameters (Figure 55). The final electron density map (2Fo-Fc) for the 
active site region of cKGA shows the well defined electron density for the DON 
molecule (Figure 56). The complex structure of cKGA: DON shows that the inhibitor 
form covalent bond contact with the side chain hydroxyl (OH) group of the catalytic 
nucleophile Ser286 (1.4 Å) and is conserved among all KGA isoforms. This is clearly 
evident from the observed continuous electron density from the active-site residue Ser286 
with the inhibitor and indicates the possibility of covalent interaction. Based on the 
structure we reveal that cKGA interacts and remove the diazo group from the 6-Diazo-5-
oxo-L-norlucine (cKGA-DON), thereby covalently connecting the enzyme with 5-oxo-l-
norleucine (ON), and forms cKGA-ON complex.  
 
The complex structure of cKGA: DON shows that the inhibitor is positioned in the 
catalytic pocket through several hydrogen bonding, and hydrophobic interactions. The 
bound inhibitor makes several interactions with Gln285, Ser286, Asn335, Glu381, 
Asn388, Tyr414, Tyr466, and Val484 (Figure 3.4). The cKGA: DON complex, the 
carbonyl oxygen of the inhibitor makes two hydrogen bonding interactions with 
backbone amino (NH) groups of Ser286 (2.9 Å and Val484 (2.8 Å), and forms an 
oxyanione hole. The α-carboxyl oxygens of the inhibitor makes two hydrogen bonding 
contacts with the side chains of Asn335 (3.1 Å) and Tyr414 (2.8 Å). 
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Figure 46: Interactions made by DON in the catalytic pocket of cKGA. DON is shown in 
yellow and cKGA residues are shown in cyan color. Final 2Fo-Fc electron density map 
for the DON and its covalent attachment to Ser286 of cKGA is shown. The map is 






On the other hand, the backbone NH group of the inhibitor involves in a hydrogen 
bonding contact with the side chains of Gln285 (2.7 Å) and Glu381 (2.8 Å) (Table 7).  
Besides, the hydrophobic cluster formed by the side chains of three tyrosine residues such 
as Tyr249, Tyr414 and Tyr466, which further stabilize the interactions with DON (Figure 
56). Notably the Tyr466 is located close to the DON (3.2 Å) and also close to catalytic 
Ser286 (2.7 Å), which is responsible for the proton transfer during catalysis. Previously 
we have shown that Tyr466 play key role in catalytic mechanism along with the active 
site dyad (Ser286 XX Lys289) (Thangavelu et al., 2012). The electrostatic surface 
potential of the cKGA: DON complex shows a predominantly positively charged active 
site (Figure 57), which is mainly contributed by the neighboring residues (Lys299 and 
Lys491) of the active site of KGA.  
 












DON atom cKGA atom Distance (Å) 
O5 Ser286N 2.98 
O5 Val484N 2.82 
O1 Asn335ND2 3.13 
O5 Tyr466OH 3.25 
NH Gln285OE1 2.79 
NH Glu381OE2 2.85 
O5 Tyr249OH 3.24 








Figure 47: Binding pocket of DON in the active site cleft of cKGA. (A) Electrostatic 
surface potential representation of cKGA-DON complex, DON is shown as yellow stick.  
(B) A close view of electrostatic surface potential representation shows that positively 
charged pocket around DON. (C) The residues interacts with DON in the active site cleft 










The direct one-to-one comparison (superposition) of cKGA: DON and the apo-cKGA 
revealed no significant structural changes in KGA upon interacting with DON (Figure 
58). This superposition yield a root-mean-square deviation (rmsd) of 0.3Å for 315 Cα 
atoms superimposed.   
 
                                      
Figure 48: Crystal structure of apo cKGA is superposed with cKGA: DON. The active 





3.3.4 Mutational Studies of cKGA Residues in the DON Binding Pocket 
The complex structure described in this chapter revealed the key residues of KGA that is 
essential in interactions with DON. To validate the enzymatic activity of DON-
interacting residues of KGA, we have generated alanine mutants and measured their 
activities through the glutaminase assay. Glutaminase activity assay showed that the 
mutant proteins (Tyr249A, Ser286A, Lys289A, and Tyr466A) significantly reduced the 
activity when compared to wild type cKGA (Figure 59). The structure-based mutagenesis 
study indicates that substitution of alanine in the DON-interacting residues greatly affects 
binding of the substrate. Thus, our study confirms that the putative catalytic dyad (Ser 
289 XX Lys289), other residues (Tyr249A and Tyr466A) could play a key role for the 
activity of KGA. 
 
 
Figure 49: Site directed mutagenesis of cKGA residues in the DON binding pocket. The 
activities of wild type cKGA were compared with key structure guided-cKGA alanine 
mutants. Triplicates of data sets were obtained for each of the cKGA constructs, and 






We have solved the crystal structure of cKGA in complex with glutamine analog 
inhibitor, DON, at resolution of 2.3 Å. On the basis of cKGA: DON complex structure  
we show that the DON is bound to the active site of KGA through the covalent 
modification of the residue Ser286, a catalytic nucleophile of the active site. Notably, the 
sequence and structural homologies between KGA and its homologs proteins suggesting 
a common mode of the active site inhibition mechanism. Besides, the structure based 
mutagenesis and kinetic studies were performed to validate the importance of key 
residues involved in the catalytic function of KGA. Although DON or other glutamine 
analogs such as acivicin, and azaserine has been widely used for the in vitro and in vivo 
studies and shown to have potential antitumor activity against human cancers, they lack 
selectivity and have toxicity concerns (Ovejera et al., 1979). A recent renewed interest in 
cancer metabolism raises the possibility that systematic usage of these agents may have 
effect against human cancers. In our studies, we found DON inhibits the activity of 
cKGA with an IC50 of approximately 1 mM. Hence, it is necessary to improve the affinity 
and specificity of DON using cKGA: DON complex structure to optimize the design and 








































Cancer cells exhibit a characteristic metabolism and they use glucose and glutamine as 
their major energy sources. The kidney-type glutaminase (KGA) is a key enzyme 
responsible for the process of glutaminolysis that promotes Warburg effect in cancer cells 
to thrive and become a tumour. KGA is considered to be an attractive and a promising 
molecular target for human cancer therapies. More importantly, the small molecule 
inhibitors of KGA are in the early stage of clinical development to treat human cancers. 
However, the effort to design better inhibitors of KGA and plan for new treatment 
regimes for cancers is greatly hindered due to the lack of clear understanding on the 
molecular mechanism of inhibition of KGA and how the function of KGA is controlled 
by hormones and signaling pathways inside the cells.  
 
In this thesis, we clearly showed that BPTES binds at the dimeric interface of KGA, near 
the active site. More strikingly, we show that binding of BPTES on the KGA, confers a 
drastic conformational change of a key loop (Glu312- Pro329), which is essential in 
stabilizing the catalytic pocket and thus rendering it inactive. Moreover, our site-directed 
mutagenesis study provides the molecular basis of BPTES specificity to KGA, verified 
through the mutants that mimic LGA isoform. Besides, the complex structural studies of 
a few BPTES derived inhibitors with KGA revealed the molecular basis of the potency, 
selectivity and pharmacophore feature of BPTES. The findings of this study on the 
BPTES and KGA novel allosteric inhibition mechanism provides valuable information 
for the optimization and development of improved versions of BPTES derived inhibitors 




Though KGA is a key metabolic enzyme, its regulations and linking to many 
physiological signaling pathways is not clearly understood. In the chapter II, we 
demonstrated that the KGA activity can be upregulated by phosphorylation upon 
stimulation of cells with epidermal growth factor (EGF), a hormone that is linked to 
cancer growth and metastasis in various tumours. Furthermore we have established that 
KGA activity is mediated by a key signaling node, the Ras-Raf-Mek2-Erk signaling 
pathway. Even if BPTES can inhibit KGA activity, but nothing is known about any 
possible synergism of cancer drug treatments. Interestingly, our studies show that 
combination of BPTES and U0126, a compound which blocks Mek kinase (a kinase in 
Ras-Raf-Mek2-Erk signaling pathway) is synergistic and inhibits cancer cell growth and 
proliferation. These findings open up the possibilities for developing more specific 
therapeutic agents towards KGA/Mek2-linked pathways and offer a more effective 
strategy to tackle glutamine-addicted cancers with greater efficacy. 
 
Besides BPTES, DON is a known active site inhibitor of KGA; however there is no 
structural information available for any of the human glutaminase isoforms in complex 
with any active site inhibitors. In chapter III, we have reported the structure and structure 
based studies on cKGA, in complex with DON. The complex structure revealed the DON 
binding mode on KGA and that form a covalent bond contact with active site. Moreover, 
we have performed site-directed mutagenesis to validate the importance of a few key 
residues involved in interactions with DON.  This study will lead to design and 




In conclusion, current structural, biochemical, molecular and cell-based studies provide 
detailed insights into (i) allosteric inhibition of KGA by BPTES (ii) active site inhibition 
of KGA by DON (iii) crosstalk and regulation of KGA activities by EGF-mediated Raf-
Mek-Erk signaling and (iv) synergism between KGA activity and Mek2 in cancer cell 
metabolism. These novel findings will help in designing better inhibitors and in 
development of multi-drug strategies for the treatment of cancers addicted to glutamine 
metabolism. 
 
4.2 Future directions 
The knowledge obtained through the present studies on KGA can be effectively utilized 
to generate a series of optimized next generation inhibitors of BPTES (allosteric) and 
DON (active site) analogs. Besides, the current knowledge on KGA: BPTES complex 
could be systematically expanded to discover small molecule inhibitors for other 
glutaminase isoform LGA (Liver type glutaminase). This can be achieved by 
synthesizing a new series of BPTES-modified inhibitors that can specifically interact 
with LGA isoform.  
 
As a continuation of our studies on KGA: the information of the KGA: BPTES and 
KGA: DON complex structure will be completely extended to develop chimeric (hybrid) 
inhibitors to specifically and effectively target KGA. The chimeric (hybrid) inhibitors can 
be generated using optimized individual allosteric and active-site inhibitors. These 
chimeric inhibitors will be optimized to have the desirable pharmacological properties of 
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both inhibitors.  By combining these inhibitors, it is expected that DON can help BPTES 
overcome the problem of water solubility. On the other hand, a reduced dose of DON 
may be sufficient in the presence of BPTES, thereby lowering its current toxic effects. 
Hence, compared to single inhibitors, a chimeric of DON and BPTES could offer a 
greater potent effect on glutaminase. 
 
Following the synthesis of chimeric and optimized inhibitors, kinetic characterizations 
can be performed for KGA to determine the selectivity and potency of each of the 
inhibitors. Subsequently, the structures of these optimized individual/chimeric inhibitors 
will be determined in complex with KGA. Such structural studies will further help to 
optimize the design and synthesis of these inhibitors.  BPTES and DON-derived 
individual inhibitors or their chimeric compounds can be tested alone and in conjunction 
with Mek2 inhibitors (dual-hit inhibition) for their efficacy against cancer cell 
proliferation in culture or any other cancer animal model studies. We therefore believe 
that the combined chimeric DON and BPTES, along with Mek2 inhibitor (dual-hit), will 
have greater efficacy, with minimum side-effects. The findings from these studies will 
result in the identification of potential anti-cancer agents or drug lead inhibitors that will 
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